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Abstract 
The proteasome is an ATP-dependent multi-catalytic protease that is essential for degradation of 
intracellular short-lived and regulatory proteins. Thereby it influences various processes such as 
intracellular signaling and immune response. Following infection and subsequent IFN release, three 
proteolytically active subunits are replaced by three alternative subunits 5i/LMP7, 1i/LMP2, and 
2i/MECL1, establishing the immunoproteasome. This proteasome sub-type is not only induced upon 
inflammation but is predominantly expressed in hematopoietic derived cells such as macrophages 
and granulocytes. These cells constitute the first line of defense against invading pathogens 
suggesting a potential role of immunoproteasomes in the initial phase of infection. Recent data 
provide evidence for crucial functions of immunoproteasomes for an efficient immune response 
against invasive microorganisms, including viral infections, parasitic infections, and intracellular 
bacterial infections. So far, no data exist discussing the influence of immunoproteasomes on the 
outcome of an extracellular bacterial infection. The extracellular bacterium Streptococcus 
pneumoniae is the leading causative pathogen in community acquired pneumonia which is still a 
major cause of morbidity and mortality. To clarify the impact of immunoproteasomes on the innate 
immune response against S. pneumoniae, we characterized the progression of disease and analyzed 
the local as well as systemic innate immune response in 5i/LMP7-/- mice by using a S. pneumoniae 
infection model. Data showed that β5i/LMP7-/- mice suffered from a more severe case of pneumonia 
which ended in a systemic inflammatory response syndrome indicated by aggravated clinical signs, 
diagnostic parameters, and immune suppression. The systemic inflammatory response probably 
established in consequence of an increased bacteremia and resulted in early mortality. Although, 
bacterial killing efficiency of 5i/LMP7-/- leukocytes was unaffected ex vivo, 5i/LMP7-/- mice 
exhibited a reduction in the expression of opsonizing molecules, facilitating bacterial uptake and 
intracellular elimination. Opsonin expression was only diminished in cells constitutively expressing 
immuno-subunits such as macrophages and liver cells. Proteasome expression was not influenced by 
S. pneumoniae, though it has changed due to 5i/LMP7 deficiency. WT macrophages mostly 
assembled 20S proteasomes containing immuno- and standard subunits, while 5i/LMP7-/- 
macrophages assembled 20S proteasomes mainly containing standard subunits. These 
proteasomal alterations were accompanied by changes in the pathogen induced activation of nuclear 
factors regulating gene transcription. 
Taken together, 5i/LMP7 deficiency altered proteasome composition in macrophages and liver that 
remodeled pathogen induced intracellular signaling, which led to diminished opsonin expression and 
increased bacteremia. The high bacterial burden caused a more severe case of pneumonia with early 
mortality. These results highlight a yet unsuspected role for immuno-subunits in modulating the 
innate immune response to extracellular bacterial infections. 
Zusammenfassung 
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Zusammenfassung 
Das Proteasom ist eine multikatalytische ATP-abhängige Protease, die kurzlebige und regulatorische 
Proteine abbaut und dabei verschiedene zelluläre Prozesse wie z.B. Signaltransduktion oder 
Immunreaktion beeinflusst. Während einer viralen Infektion oder Entzündungsreaktion, die mit einer 
IFN Freisetzung einhergeht, werden drei katalytischen Untereinheiten durch alternative 
Untereinheiten (β1i/LMP2, β2i/MECL-1, β5i/LMP7) ersetzt und so das Immunoproteasom 
assembliert. Dieser Proteasom Subtyp ist nicht nur induziert sondern auch konstitutiv exprimiert in 
Zellen hämatopoetischen Ursprungs, wie z.B. Makrophagen und Granulozyten. Diese Zellen gehören 
zum angeborenen Immunsystem und bilden die erste Angriffsfront gegen pathogene 
Mikroorganismen. Dies lässt auf eine wichtige Rolle des Immunoproteasoms in der Immunabwehr 
schließen, insbesondere in der Anfangsphase einer Infektion. Aktuelle Untersuchungen zeigen dessen 
Bedeutung für eine effiziente Immunantwort gegen Krankheitserreger, wie Viren, Parasiten und 
intrazelluläre Bakterien. Jedoch wurden bisher keine Daten veröffentlicht, die dessen Einfluss auf den 
Krankheitsverlauf einer extrazellulären bakteriellen Infektion diskutieren. Das extrazelluläre 
Bakterium Streptococcus pneumoniae ist der Hauptkrankheitserreger der Pneumonie, eine 
Infektionskrankheit mit hoher Krankheits- und Sterblichkeitsrate. Um die Bedeutung des 
Immunoproteasoms für die angeborene Immunantwort bei einer S. pneumoniae Infektion auf zu 
zeigen, charakterisierten wir den Krankheitsverlauf einer bakteriellen Pneumonie und analysierten 
lokale aber auch systemische Immunreaktionen in 5i/LMP7-/- Mäusen mit Hilfe eines S. pneumoniae 
Infektionsmodels. Die hier generierten Daten zeigten einen fortgeschrittenen Krankheitsverlauf in 
5i/LMP7-/- Mäuse, der in einem systemischen inflammatorischen Response-Syndrom endete und 
sich in klinischen Parametern, wie physiologische Kondition, spezifische diagnostische Marker und 
Immunsuppression, andeutete. Der Zustand der Sepsis entwickelte sich aufgrund einer erhöhten 
bakteriellen Last im Blut und führte zu einer vorzeitigen Mortalität infizierter 5i/LMP7-/- Tiere. 
Obwohl die Fähigkeit von 5i/LMP7-/- Leukozyten ex vivo Bakterien zu eliminieren nicht 
beeinträchtigt war, zeigten 5i/LMP7-/- Mäuse in vivo eine verminderte Expression von 
opsonierenden Molekülen. Diese Moleküle fördern die Aufnahme, Elimination und Degradation 
pathogener Mikroorganismen. Deren Expression war ausschließlich in Gewebe und Zellen 
beeinträchtigt, die unter WT Bedingungen immunoproteasomale Untereinheiten konstitutive 
exprimieren, wie Makrophagen und Lebergewebe. Obwohl S. pneumoniae die proteasomale 
Zusammensetzung in Makrophagen und Lebergewebe nicht beeinflusst, gab es generelle 
Unterschiede zwischen WT und 5i/LMP7-/- Tieren. WT Makrophagen inkorporierten sowohl 
immuno- als auch standard- Untereinheiten, während 5i/LMP7-/- Makrophagen vor allem 
Standardproteasome assemblierten. Die Veränderung in der proteasomalen Zusammensetzung ging 
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mit einer modifizierten Pathogen-induzierten Aktivierung nuklearer Faktoren einher, die die 
Genexpression inflammatorischer Moleküle regulieren. 
Zusammengefasst lässt sich sagen, dass das Fehlen der katalytischen immunoproteasomalen 
Untereinheit 5i/LMP7 die proteasomale Zusammensetzung in Makrophagen und Lebergewebe 
verändert, was mit einer Modulierung der Aktivität nuklearer Faktoren einhergeht. Dies führt zu 
einer verminderten Opsoninexpression und verstärkten Bakteriämie. Die erhöhte bakterielle Last 
führt zu einem schwereren Krankheitsverlauf der Pneumonie mit vorzeitiger Mortalität. Diese 
Ergebnisse unterstreichen eine bisher unbekannte Rolle immunoproteasomaler Untereinheiten bei 
der Regulierung der angeborenen Immunantwort während einer extrazellulären bakteriellen 
Infektion. 
 
  
 
Introduction 
1 
 
1. Introduction 
 
1.1. Ubiquitin proteasome system 
The ubiquitin proteasome system (UPS) is the primary non-lysosomal ATP-dependent protein 
degradation machinery in eukaryotic cells (Rock et al. 1994). By degrading short-lived poly-ubiquitin-
tagged substrates it determines the availability of regulatory proteins and controls a large number of 
physiologically important cellular processes such as cell cycle progression, apoptosis, cell 
differentiation, gene regulation, inflammatory response, and antigen presentation (Ebstein et al. 
2012). For example, cell cycle progression is controlled by selective degradation of cyclins (Hershko 
et al. 1991). The UPS preserves cell viability by preventing accumulation of irreversibly damaged and 
potentially toxic proteins (Seifert et al. 2010), and, by controlling levels of transcription factors, such 
as NFB, the UPS influences gene transcription (Collins & Tansey 2006).  
A chain of at least four ubiquitins (poly-ubiquitination), created by attaching additional ubiquitin 
moieties to one of the seven internal lysine residues at the position 48 (K48) of already attached 
ubiquitins, is the classical recognition motif for proteasomal degradation (Amm et al. 2014; Hershko 
& Ciechanover 1998). Also multi-ubiquitination, defined as addition of single ubiquitins to several 
different lysine residues of one target protein, is described to serve as signal for proteasomal 
degradation (Lu et al. 2015). The attachment of an ubiquitin moiety to a lysine residue is achieved via 
an ATP-dependent enzymatic cascade involving three classes of enzymes: Ubiquitin-activating 
enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3) (Komander 2009). 
Whether a protein is degraded or otherwise modified depends on the structure of the ubiquitin 
chain. Modifications with a single ubiquitin molecule (mono-ubiquitination) or with chains of other 
linkage types (K6, K11, K27, K29, K33, K63, M1) are not degraded by the proteasome but are 
recognized as physiological target motifs, playing a role in cell regulation (Komander 2009). For 
example, mono-ubiquitin plays a role in histone regulation and DNA repair, K11-linked poly-ubiquitin 
is involved in cell-cycle regulation, K33-linked poly-ubiquitin is involved in kinase modification, and 
K63-linked poly-ubiquitin is involved in endocytosis, DNA-damage responses and in signaling 
processes (Pickart & Eddins 2004; Komander 2009; Hershko & Ciechanover 1998). Linear poly-
ubiquitin, linked via an N-terminal methionine (M1) is supposed to play a role in cell signaling 
(Komander 2009). 
  
1.1.1. 26S proteasome  
The 26S proteasome (Figure 1.1) is the proteolytic enzyme of the UPS. It is structurally and 
functionally divided into two sub-complexes: The 20S proteasome core particle, where substrate 
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proteolysis occurs, and the 19S regulatory particle, which is involved in the recognition, unfolding, 
and translocation of ubiquitin-tagged substrates (Voges et al. 1999; Gallastegui & Groll 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Structure of the 26S proteasome and proteolytic cleavage of ubiquitinated substrate. 
(A) The 26S proteasome consists of the 19S regulator particle and the 20S core complex. The 19S 
regulator is bound to either or both ends of the 20S core. The 19S particle consist of two sub-
complexes, base and lid. The 20S core particle consist of two - and two -heptamic-rings, arranged 
in an stoichiometry, forming a cylindrical barrel-like structure. The -rings comprise the 
catalytic activity. (B) At the 19S proteasome the ubiquitin chain is disassembled and the substrate is 
unfolded before it can enter the cavity of the 20S core particle where proteolysis takes place (figure 
modified from Kaiser & Huang 2005). 
 
The 20S proteasome core particle is a barrel-shaped complex that is composed of four stacked 
heptameric rings, enclosing a central cavity. It is formed by two outer -rings and two inner -rings, 
each made up of seven distinct- and -subunits displaying an  organization (Unno et 
al. 2002; Huber et al. 2012). The catalytic activity is restricted to three -subunits (1, 2, and 5) 
that expose N-terminal threonine residues, which display a nucleophile hydrolase activity for peptide 
bound cleavage. The catalytically active 1-, 2-, and 5-subunits account for the caspase-like, 
trypsin-like, and chymotrypsin-like activities of the proteasome reflecting cleavage specificities after 
acidic, basic, and hydrophobic amino acid residues, respectively (DeMartino & Slaughter 1999, 
Orlowski & Wilk 2000). Access to the active center of the 20S chamber is regulated by an adjustable 
gate that is formed by the N-termini of the -subunits. When a regulator particle binds to the outer 
-rings, it causes a structural rearrangement of the N-terminal portions of the -subunits that opens 
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the central chamber and facilitates access of proteins to the catalytic core (Groll et al. 1997; Unno et 
al. 2002; Gallastegui & Groll 2010). In the absence of a regulator particle, the free 20S proteasomes 
show detectable but low activity towards small proteins with intrinsically unstructured regions in the 
absence of ubiquitin and ATP (Baugh et al. 2009).  
The 19S regulator particle is formed by two sub-complexes, lid and base (Gallastegui & Groll 2010). 
The base is composed of six homologous ATPases (Rpt1-Rpt6) that form a hexameric ring. Additional 
four non-ATPases (Rpn1/2, Rpn10/13), including two ubiquitin receptors, Rpn10 and Rpn13, are 
associated to the hexameric ring. The lid consist of nine non-ATPase subunits including Rpn11, 
displaying deubiquitinating activity (Lander et al. 2012; Tanaka et al. 2012). 
 
1.1.2. Proteasome sub-types 
In response to IFN three alternative proteolytically active -subunits, β1i/LMP2, β2i/MECL-1, and 
β5i/LMP7 are incorporated into a nascent 20S proteasome generating a new sub-type, named 
immunoproteasome (Aki et al. 1994). In the mouse, β1i/LMP2 and β5i/LMP7 are encoded within the 
major histocompatibility complex (MHC) class II region on chromosome 17, while β2i/MECL-1 is 
localized in a cluster of unrelated genes on chromosome 8  (Ferrington & Gregerson 2012).  
The assembly of 20S proteasomes (Figure 1.2) is similar for all proteasome sub-types. It is guided by 
proteasome-assembling chaperones (PAC1/2, PAC3/4) which facilitate the formation of a closed 
heptameric -ring. Subsequently, in case of the standard proteasome the -ring formation starts 
with the incorporation of the first pro--subunit 2 assisted by the proteasome maturation protein 
(POMP). The remaining -subunits (3-7) incorporate into the nascent complex and form an 
inactive half proteasome (Sahara et al. 2014). Finally, two half proteasome core particles are 
combined, assisted by POMP (Fricke et al. 2007; Krüger et al. 2001). This initiates maturation of the 
proteolytically active -subunits (1, 2, 5) by lysis of their pro-peptides. The last step is essential 
for activation of the catalytic threonine residues (Ditzel et al. 1998). The assembly of the 
immunoproteasome is favored over the standard proteasome, due to its cooperative manner (Griffin 
et al. 1998). In cells co-expressing both standard and immuno-subunits, β1i/LMP2 is the first 
incorporated-subunit, while 1 is integrated later during the assembly process (De et al. 2003). The 
presence of β1i/LMP2 supports the incorporation of β2i/MECL-1 (Groettrup et al. 1997). 
Furthermore, POMP binds with high affinity to β5i/LMP7 and not to the 5 pro-peptide (Heink et al. 
2005). The incorporation of β5i/LMP7 is required for the maturation of nascent immuno- 20S core 
particles by assisting the catalytic lysis of the pro-peptides of β1i/LMP2 and β2i/MECL-1 (Ferrington 
& Gregerson 2012).  
Incorporation of immuno-subunits has been linked with altered chymotrypsin-like and caspase-like 
activities. β5i/LMP7 and β2i/MECL-1 display the same cleavage specificity as its homologous standard 
Introduction 
 
4 
 
subunit, but, in contrast to its standard caspase-like 1-subunit, the β1i/LMP2 subunit provides 
chymotrypsin-like activity (Gaczynska et al. 1994; Basler et al. 2013). The altered caspase-like activity 
of β1i/LMP2 is explained by an amino acid substitution in the β1i/LMP2 substrate binding pocket 
which changes the catalytic core more hydrophobic and constricted. Structural modifications in the 
substrate binding pocket result in altered cleavage preference and changes the quantity of peptides, 
generated and presented on MHC class I molecules (Huber et al. 2012; Mishto et al. 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Assembly of 20S proteasome sub-types. The assembly of 28 α- and β-subunits into a 20S 
core particle begins with the formation of an α-ring which occurs with the aid of the chaperone 
heterodimer complexes PAC1/2 and PAC3/4. It is followed by the -ring formation which, in case of 
the standard proteasome (A) starts with the association of the pro-β2-subunit on the α-ring 
facilitated by the chaperone POMP. The subsequent sequential incorporation of other -subunits 
leads to the formation of half-proteasomes. Two half-proteasomes dimerize and form a 4-ring 
heptamer that, results in catalytic cleavage of the pro-β-subunits. (B) One (5i/LMP7) or two 
(2i/MECL-1 and 5i/LMP7) immuno-subunits can incorporated in nascent standard proteasomes 
forming intermediate proteasomes. (C) Immunoproteasome assembly occurs in a cooperative 
manner. 1i/LMP2 enters the assembly pathway earlier than the standard 1-subunit. The presence 
of 1i/LMP2 abets the incorporation of 2i/MECL-1 which abets the incorporation of 5i/LMP7. 
Incorporation of immuno-subunits is favored, indicated by the thickness of the arrows.  
 
β5i/LMP7 is the only immuno-subunit that can be incorporated into proteasomes independent of the 
other subunits (Ferrington & Gregerson 2012). This allows the existence of intermediate 
proteasomes (Figure 1.2), which incorporate only one or two immuno-subunits (Gohlke et al. 2014; 
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Dahlmann et al. 2000). It is also possible that an asymmetric hybrid proteasome, consisting of 
immunoproteasome and constitutive proteasome, exists (Klare et al. 2007). Intermediate 
proteasomes are present in liver and colon, but not in heart and are mostly abundant in professional 
antigen presenting cells such as macrophages and DCs (Guillaume et al. 2010). Intermediate 
proteasomes have altered cleavage preferences in generating class I peptides (Guillaume et al. 2012). 
 
Another protein complex induced by IFN is the proteasome regulator particle PA28. It is a large 
regulatory complex that binds the ends of the 20S proteasome in an ATP-independent manner, 
facilitating -ring opening. (DeMartino & Slaughter 1999). PA28 is a hetero-heptameric ring made of 
two homologous subunits, PA28 and PA28. A third PA28 family member, the PA28 is structurally 
related, forms homopolymeric complexes, and is associated with 20S proteasomes predominantly in 
the nucleus, but is not inducible by IFN (Tanahashi et al. 1997). PA28 can attach to both sides of the 
20S core (PA28-20S-PA28) or it is found in complexes that also contain a 19S regulator, forming a so 
called hybrid proteasome (19S-20S-PA28) (Tanaka et al. 2012). Binding of PA28 to 20S cores 
increases substrate affinity and enhances either the uptake of substrates or release of products (Sijts 
et al. 2002). 
 
1.1.3. Functions of immunoproteasomes during disease 
Immunoproteasomes are involved in biological and pathological processes resulting in the 
development and aggravation of many diseases, including neurodegenerative diseases, inflammatory 
and autoimmune diseases, and viral and intracellular bacterial infections (Ferrington & Gregerson 
2012). For example, the expression of immuno-subunits in non-lymphoid tissues is low but also 
strongly upregulated upon immunological and/or pathological challenge (Ebstein et al. 2012). Under 
healthy conditions immunoproteasomes are absent in neurons but are induced in animal models of 
neurodegenerative diseases such as Alzheimer´s disease (Mishto et al. 2006), Huntington´s disease 
(Díaz-Hernández et al. 2003), and amyotrophic lateral sclerosis (Puttaparthi et al. 2007). Elevated 
immunoproteasome levels have been reported in a number of autoimmune and inflammatory 
diseases, such as Crohn´s disease, ulcerative colitis, and hepatitis.  A pronounced 
immunoproteasome expression was found in intestinal tissue of patients with Crohn´s disease 
(Visekruna et al. 2006), in liver of patients with cirrhosis (Vasuri et al. 2010), and in clinical samples of 
multiple sclerosis patients (Mishto et al. 2010). Furthermore, immunoproteasome formation was 
documented in microglia cells in response to infection with Lymphochoriomeningitis virus (LCMV) 
(Kremer et al. 2010), and in liver cells in response to infection with Listeria monocytogenes (Khan et 
al. 2001). 
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However, expression of immuno-subunits is not only induced upon inflammation (Aki et al. 1994) but 
is predominantly expressed in hematopoietic derived cells such as splenocytes, macrophages, and 
DCs (Ebstein et al. 2012). The constitutive expression of immuo-subunits is likely due to a permanent 
activation of intracellular signaling mechanisms. It has been shown that permanent 
unphosphorylated Stat1 binds IRF1 to form a complex which functions as transcription factor, 
constantly supporting β1i/LMP2 expression in hematopoietic derived cells (Ebstein et al. 2012; 
Chatterjee-Kishore et al. 2000). 
Functions of immunoproteasomes have been investigated by studying animal infection or 
inflammation models using immunoproteasome deficient mice (reviewed in Ebstein et al. 2012; 
Ferrington & Gregerson 2012; Basler et al. 2013; Miller et al. 2013), and were complemented by 
descriptions of diseases in humans linked to mutations or single-nucleotide polymorphisms in genes 
encoding immuno-subunits (reviewed in McDermott et al. 2015). Furthermore, the use of selective 
immunoproteasome inhibitors helped to identify immunoproteasome involvement in a variety of 
immunological and physiological processes (reviewed in Kisselev & Groettrup 2014). 
Proteasomes play a major role in generating peptides presented on MHC class I molecules that are 
recognized by CD8+ cytotoxic T cell receptors (Rock et al. 1994). Immunoproteasome cleavage 
preferences alter the versatility of antigen processing and the possibility to generate and present 
immunogenic epitopes that contribute to an efficient anti-bacterial and anti-viral cellular immune 
response (reviewed in Ebstein et al. 2012; Groettrup, Kirk, and Basler 2010). For example, β5i/LMP7-/- 
mice exhibited a diminished generation of an epitope of the intracellular bacterium Listeria 
monocytogenes (Strehl et al. 2006), β1i/LMP2 deficiency resulted in a depressed response to a 
nucleoprotein epitope of influence A virus (IAV) (Van Kaer et al. 1994), and mice deficient in 
β1i/LMP2 or β2i/MECL-1 had a decreased CD8+ cytotoxic T cell response to class I restricted epitopes 
of LCMV (Basler et al. 2006; Chen et al. 2001). In recent years it became apparent that 
immunoproteasomes not only function by generating MHC-I epitopes, but also possess additional 
immunological functions. However, whether immunoproteasome deficiency exerts a protective 
effect or exacerbates disease depends on the underlying pathology and/or inflamed tissue (reviewed 
in Ferrington and Gregerson 2012; Tanaka et al. 2012).  
Immunoproteasome formation is essential for preservation of cell viability, as immunoproteasomes 
protect cells against harmful inflammation-induced accumulation of protein aggregates more 
efficiently than standard proteasomes (Seifert et al. 2010). For example, β5i/LMP7-/- mice failed to 
clear protein aggregates that accumulated in cardiomyocytes following Coxsackie virus B3 (CVB3) 
infection. Therefore, β5i/LMP7 deficient mice suffered from an aggravated myocarditis, which occurs 
in consequence of an impaired protection against virus-mediated protein damage (Opitz et al. 2011). 
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Immunoproteasomes are also crucial for the regulation of cell proliferation and differentiation. Mice 
deficient in β1i/LMP2 or β2i/MECL-1 exhibited significant reduced numbers of naive cytotoxic T cells 
(Van Kaer et al. 1994; Basler et al. 2006). Additionally, β1i/LMP2-/-, β5i/LMP7-/-, or β2i/MECL-1-/- T 
cells were unable to expand and survive when transferred into virus infected WT hosts (Moebius et 
al. 2010). The diminished proliferation of CD8+ cytotoxic T cells is assumed to be intrinsically 
regulated by the proteasome (Zaiss et al. 2008). Furthermore, β5i/LMP7 deficiency resulted in 
diminished CD4+ Th1 and Th17 differentiation, and enhanced development of regulatory T cells, 
examined during the case of an experimental colitis (Kalim et al. 2012).  
Pathophysiological functions of immunoproteasomes have been investigated in the context of auto-
inflammatory diseases. For example, immunoproteasome deficiency is accompanied by an 
attenuation of pathological signs of experimental colitis. Deficient mice show no induction of pro-
inflammatory cytokines such as TNF, IL-6, IL-17, IL-23 and IL-1 and have less intestinal 
inflammation (Schmidt et al. 2010). The same positive effect on pathological signs of experimental 
colitis was documented in WT mice pretreated with a 5i/LMP7 specific inhibitor (Basler et al. 2010). 
By using subunit-selective inhibitors it is possible to investigate how enzymatic activity, rather than 
absence of immuno-subunits, influences immunological and pathological functions. Treatment with a 
β5i/LMP7 specific inhibitor protected mice from several different auto-inflammatory diseases, 
showing reduced pathological signs and inflammation. It prevented the development or progression 
of experimental arthritis (Muchamuel et al. 2009), systemic lupus erythematosus (SLE) (Ichikawa et 
al. 2012), experimental colitis (Basler et al. 2010), and experimental auto-immune encephalomyelitis 
(EAE) (Basler et al. 2014). Interestingly, β5i/LMP7 inhibition did not consistently provoke the same 
effect on disease development as β5i/LMP7 deficiency. For example, β5i/LMP7 inhibition and not 
deficiency protected mice from disease in an experimental EAE model (Basler et al. 2014). 
 
These studies underline the role of immunoproteasomes in specific signaling pathways, probably by 
elevating the protein turnover rate of critical signaling molecules (Ebstein et al. 2012). Some of this 
issue is described in more detail in section 1.2.3. (Figure 1.4). 
A manifested expression of immunoproteasomes in intestine of patients with Crohn´s disease or 
ulcerative colitis was associated with an elevated activation of the NFB signaling pathway 
(Visekruna et al. 2006). The NFB pathway is one of the main signal transduction pathways for 
responding to various stressors such as cytokines and viral as well as bacterial products (Newton & 
Dixit 2012). Its dysregulation can lead to pathologies such as neurodegenerative and inflammatory 
diseases (Małek et al. 2007). NFB is inhibited by forming a complex with IB proteins that are 
degraded by the 26S proteasome upon stimulation. This results in NFB activation and transduction 
into the nucleus (Newton & Dixit 2012). Immunoproteasomes enhance nuclear translocation by 
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degrading IB faster than standard proteasomes (Seifert et al. 2010; Visekruna et al. 2006). An 
impaired NFB activation was observed in β5i/LMP7-/- mice upon CVB3 infection (Opitz et al. 2011), 
which was also documented in β1i/LMP2-/- B cells upon LPS stimulation (Hensley et al. 2010). 
Reis et al. documented reduced levels of nitric oxide (NO), produced by LPS-stimulated β5i/LMP7-/- 
macrophages, as a consequence of a diminished activation of the TRIF/TRAM signaling cascade (Reis 
et al. 2011). TRIM/TRAF are adaptor molecules that are essential in the MyD88-independent 
signaling of TLR-4 (Newton & Dixit 2012). 
Furthermore, it seems that immunoproteasomes are also involved in regulating the MAPK signaling 
pathway as increased phosphorylation of p38 with subsequent IL-6 production upon stimulation was 
documented in cells expressing a non-functional β5i/LMP7 mutant (Kitamura et al. 2011).  
It is also proposed that immunoproteasomes influence the IFN signaling pathway. For example, 
PBMCs from patients with CANDLE syndrome (further explained below) exhibited a strong STAT1 
phosphorylation in response to IFN which leads to an up-regulation of IP-10, MCP-1, and Rantes (Liu 
et al. 2012). 
 
Several recent human genetics studies, identifying missense or nonsense mutations in the PSMB8 
gene encoding β5i/LMP7, support the involvement of immunoproteasomes in inflammatory 
disorders. All patients carrying mutations in the PSMB8 gene have a decreased proteasome 
chymotrypsin-like activity and suffer from symptoms displaying recurrent fever, elevated levels of 
acute phase molecules, high levels of IL-6, and auto-immune abnormalities (McDermott et al. 2015). 
These disorders are called joint contractures, muscle atrophy, microcytic anaemia, and panniculitis-
induced lipodystrophy syndrome (JMP) (Agarwal et al. 2010), chronic atrophical neutrophilic 
dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE) (Liu et al. 2012), 
Nakajo–Nishimura syndrome (NNS) (Arima et al. 2011), and Japanese auto-inflammatory syndrome 
with lipodystrophy syndrome (JASL) (Kitamura et al. 2011). 
 
1.2. Community acquired pneumonia 
World health organization (WHO) statistics 2014 indicate that lower respiratory tract infections are 
the third leading cause of death globally and the number one cause of death in developing countries. 
(WHO 2014) 
 
1.2.1. Pneumococcal pneumonia - Epidemiology and Disease 
S. pneumoniae is estimated to cause 27 % of all cases of community acquired pneumonia, being the 
most frequent pathogen causing lower respiratory tract infections (Said et al. 2013). It is a common 
bacterium residing the upper respiratory tract, mainly as commensal flora. After colonization by one 
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of the 92 serotypes (Dockrell et al. 2012) it persists in adults for weeks and in children for months 
without any clinical signs (Dockrell et al. 2012). Airway colonization is detected in 10 % of healthy 
adults, in 20 - 40 % of healthy children and in more than 60 % of healthy infants in day-care settings 
(van der Poll & Opal 2009). Since it is easily transmitted by direct contact with contaminated 
respiratory secretions, this carrier state sustains the bacterium within human population (Bogaert et 
al. 2004).  
Incidence of invasive pneumococcal disease varies substantially by age, with children younger than 5 
years and adults older than 65 years being most at risk (Steel et al. 2013). Other risk factors comprise 
the socioeconomic status and immune status. They include decreased body weight, high alcohol 
consumption, smoking, immune compromised states such as HIV infection or asplenia, 
immunoglobulin and complement deficiencies, diabetes mellitus and other underlying co-morbidities 
(Torres et al. 2013).  
Various pneumococcal vaccines are available for preventing pneumococcal disease. The most widely 
used 23-valent vaccine protects against only 23 out of over 92 serotypes worldwide and covers 
serotypes prevalent mostly in North America, Europe, and Australia (Kadioglu & Andrew 2004). 
Nevertheless, since the year 2000 there has been a dramatic decline in invasive pneumococcal 
disease in children as well as in adults in countries, where the vaccine has been used (Anon 2008). 
S. pneumoniae infect humans, monkeys, rabbits, horses, and mice causing pneumonia, otitis media, 
meningitis, and bacteremia depending on the serotype (Henriques-Normark & Tuomanen 2013). It 
usually begins with mild upper-airway irritation, but when bacteria reach the lower respiratory tract 
systemic inflammation ensues with characteristic signs and symptoms. The onset of severe illness 
develops with fever, malaise, cough, and dyspnoea. Left untreated, this toxic illness can progress to 
acute respiratory failure, septic shock, multiorgan failure, and death within several days (Lynch & 
Zhanel 2009). Despite advances in medical care, mortality remains high. A recent cohort study 
estimated the 28-day mortality in patients, hospitalized due to community acquired pneumonia, to 
13 % in South America, 9 % in Europe, and 7 % in North America (Arnold et al. 2013).  
Multiple antibiotic resistance has rapidly increased in the last decade and covers the globe varying by 
geographic location. A recent US study demonstrated 21 % drug resistance to clindamycin, 39 % to 
erythromycin, and 21 % to oral penicillin (Pfaller et al. 2012). Since antibiotics are still the only choice 
of treatment and antibiotic resistance spreads S. pneumoniae remains a critical pathogen (Remington 
& Sligl 2014).  
 
1.2.2. Streptococcus pneumoniae – Genetics and Virulence 
Streptococcus pneumoniae are encapsulated Gram-positive diplococci that grow in pairs or chains 
and belong to the group of -streptococci. They are -hemolytic and live facultative anaerobe 
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(Watson et al. 1993). At least 92 different serotypes are known, which can be distinguished by their 
polysaccharide capsule and differ in virulence (Dockrell et al. 2012).  
The pneumococcal genome is a covalently closed, circular DNA structure often accompanied by small 
cryptic plasmids. It contains a core set of more than 1500 genes that are essential for viability. 
Additional genes encode virulence factors and others maintain a non-invasive phenotype. 
Pneumococci cluster virulence genes into small defined sequences known as regions of diversity. 
These regions distinguish invasive from non-invasive strains (Tettelin et al. 2001). Pneumococci have 
a large number of insertion sequences and some strains contain transposons that mediate antibiotic 
resistance and are obtained by horizontal gene transfer (van der Poll & Opal 2009). Furthermore, the 
genome contains many copies of direct-repeat DNA elements that provide recombination hotspots 
for genetic variability. These spots are related to genes for example encoding capsular biosynthesis 
and adhesins (Dockrell et al. 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Selected virulence factors of S. pneumoniae and its main function. Polysaccharide 
capsule (Cps), pneumolysin (Ply), pneumococcal surface antigen A (PsaA), pneumococcal surface 
protein A  (PspA), lipoteichonic acid (LTA), neuraminidases (NanA), enolase (Eno), pneumococcal 
adhesion and virulence (pavA), hyaluronidase (Hyl), autolysin (LytA), choline binding protein A 
(CbpA), IgA1 protease (IgA1), pili (figure modified from van der Poll & Opal 2009). 
 
S. pneumoniae express various virulence factors determining its invasiveness (Figure 1.3). Among 
these factors the polysaccharide capsule and the pneumolysin are the most essential virulence 
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determinants (Kadioglu et al. 2008). The polysaccharide capsule is crucial during colonization, 
invasion, and dissemination from the respiratory tract. Its morphology alternates between two 
distinct phases known as the transparent (thin) and opaque (thick) phenotype. S. pneumoniae with a 
transparent phenotype express less pneumococcal surface protein (PspA) and more choline-binding 
protein A (CbpA), while pneumococci with an opaque phenotype express more PspA and less CbpA 
(Ogunniyi et al. 2002). Transparent capsules are favored in early colonization, in order to support 
adhesion, while opaque capsules are favored during invasion in order to resist complement-
mediated opsonophagocytosis (Bogaert et al. 2004; Kadioglu et al. 2008; Henriques-Normark & 
Tuomanen 2013). Thick capsules reduce opsonisation by sterically inhibiting the interaction of C3b, 
fixed to pneumococci, and the CR3 receptor, expressed by phagocytes (Hammerschmidt et al. 2005).  
Pneumolysin is an exotoxin, released during autolysis, facilitated by autolysin (LytA). It is expressed 
by almost all invasive strains since negative mutants are less likely to produce lethal pulmonary 
infections (Hirst et al. 2004; Kadioglu et al. 2008). This pore-forming toxin is a soluble monomer that 
intercalates and oligomerizes in host membranes and thereby lyses the cell. Beside its cytotoxicity, 
pneumolysin has many other pathological effects, including activation of CD4+ T cells, decrease of 
respiratory burst of phagocytes, induction of chemokine and cytokine production, and activation of 
complement fixation (Mitchell & Mitchell 2010; Hirst et al. 2004; Kadioglu et al. 2008).  
 
1.2.3. Immunology – Immune Recognition and Innate Immune Response 
The immune system employs numerous mechanisms to protect the host from an invasive 
pneumococcal infection. Release of bacterial cell-wall particles, toxins, and DNA, facilitated by 
autolysis, initiates activation of these defense mechanisms (Koppe et al. 2012). These bacterial 
components contain conserved motifs that are referred to as pathogen-associated molecular 
patterns (PAMPs). This motifs are recognized by pattern-recognition receptors (PRRs) which are 
crucial components of the innate immune system (Newton & Dixit 2012).  
PRRs belong to different protein families including Toll-like receptors (TLRs), nucleotide-binding 
oligomerization domain receptors (NOD-like receptors, NLRs and AIM2), and cytosolic DNA sensors 
(Koppe et al. 2012; Akira et al. 2006). TLRs can detect pneumococcal components at either the cell 
surface, in lysosomes, or endosomes. Lipoteichonic acid and proteoglycan is recognized by TLR-2 
(Knapp et al. 2004), pneumolysin interacts with TLR-4 (Malley et al. 2003), and CpG-motif containing 
DNA is detected by TLR-9 (Newton & Dixit 2012). Receptors of the NLR family such as NOD2 
recognize pneumococcal proteoglycans, while other members, such as NLRP3 or AIM2 bind 
pneumolysin or cytosolic DNA, respectively, and form protein complexes called inflammasomes, 
which mediate cleavage of pro-IL-1 into mature IL-1 (Koppe et al. 2012).  
 
Introduction 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: S. pneumoniae induces intracellular signaling. Binding of LTA, Ply, and CpG containing 
DNA on TLR-2, TLR-4, and TLR-9 triggers interactions between the cytosolic TIR domain of the TLRs 
and TIR-containing adaptor proteins (MAL and TRAM). MAL recruits the adaptor protein MyD88 that 
binds and activates IRAK4 which phosphorylates IRAK1, initiating auto-phosphorylation. 
Phosphorylated IRAK1 dissociates from the complex and activates TRAF6. Phosphorylated TRAF6 
triggers the activation sequence TAB2 - TAK1 - IKK-complex. IκB phosphorylation and ubiquitination 
by the IKK-complex leads to its degradation by the proteasome and release and translocation of NF-
κB (p65, p52) to the nucleus for gene regulation. Furthermore, TAK1 also activates MKKs for 
subsequent JNK, ERK, and p38 phosphorylation, leading to AP-1 (cJun, cFos, ATF-2) activation that 
triggers gene transcription of cytokines and inflammatory molecules. TLR-4 can also signal via the 
adaptor proteins TRAM and TRIF. TRAF6 and RIP1 interact with TRIF to signal NFB activation, but 
also stimulate IRF3-dependent transcription via TBK1 and TRAF3. IRF3-dependent transcription can 
also be activated via STING by binding of CpG containing DNA to cytosolic DNA sensors. NOD2, 
activated by peptidoglycans, recruits and activates RICK that triggers the activation sequence TAB2 - 
TAK1 - IKK-complex which leads to ubiquintination and degradation of IB by the proteasome, 
resulting in production of NFB dependent cytokines. The NLRP3 and AIM2 inflammasomes, 
activated by Ply and bacterial DNA, respectively, mediate cleavage of pro-IL-1 into mature IL-1 
(figure modified from Qureshi et al. 2012; Koppe et al. 2012). 
 
TLRs as well as NOD2 stimulate the production of NFB and AP-1 dependent cytokines (Figure 1.4), 
including TNF, IL-6, pro-IL-1, as well as chemokines such as CXCL-1 and MIP-1 via the MyD88, 
TRIM/TRAF, and MAPK pathway (Koppe et al. 2012). Sensing of S. pneumoniae DNA by cytosolic DNA 
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receptors activate the transcription factor IRF3, and stimulate type I IFN responses (Koppe et al. 
2012; Newton & Dixit 2012) 
PRR signaling results in activation of innate immune defenses (Figure 1.5). The very first line of innate 
immune defense is the respiratory epithelium (Diamond et al. 2000). Beside its barrier function, 
alveolar epithelial cells help to clear S. pneumoniae by releasing protective inflammatory mediators 
including chemokines such as CXCL-1 and MIP-1, opsonizing molecules such as pulmonary 
surfactants called surfactant protein A and D (SP-A and SP-D), and antimicrobial peptides such as 
lysosomes and defensins (Bals & Hiemstra 2004). SP-A and SP-D are collectins and play a role in the 
protection of the host by binding and opsonizing microbes (Hartshorn et al. 1998). SP-D deficient 
mice showed increased susceptibility to S. pneumoniae infection (Jounblat et al. 2005) while SP-A 
promoted phagocytosis in in vitro experiments (Kuronuma et al. 2004) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Inflammation in invasive pneumococcal pneumonia. Pathogen recognition by alveolar 
macrophages initiates production of inflammatory mediators including TNF-, IL-1, IL-6, and IFN, 
as well as opsonins such as PTX-3 and C1q. IL1- and TNF further stimulate alveolar epithelial cells 
to produce inflammatory mediators such as CXCL-1 and MIP-1 which stimulate recruitment of 
phagocytes. Alveolar epithelial cells also upregulate the synthesis of collectins (SP-A and SP-D), which 
sequester bacteria for opsonophagocytosis. DCs maturate and activate T cell responses. If alveolar 
defense mechanisms are overwhelmed by pneumococci replication, invasion of S. pneumoniae into 
the bloodstream takes place. In the bloodstream, bacteria have to combat various host proteins 
including natural IgG and IgM, CRP, and complement components such as MBL, Ficolin, and C1q 
(figure modified from Opitz et al. 2010).  
 
Alveolar macrophages represent the first phagocytic defense and are essential in initiating and 
coordinating the innate immune response to infection (Cole et al. 2014). In addition to phagocytosis 
and endosomal clearance of S. pneumoniae, they rapidly produce large amounts of pro-inflammatory 
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cytokines such as TNF, IL-1IL-6, and IFNas well as reactive oxygen species (ROS) and nitric oxide 
(NO). They are activated by PAMPs but also by cytokines, complement, and antibody complexes 
(Marriott & Dockrell 2007; Braun et al. 1999) and finally contribute to the resolution of inflammation 
in lung tissue by clearing apoptotic cells (Aberdein et al. 2013).  
In established pneumonia neutrophils become the major cells eliminating bacteria. Chemokines such 
as CXCL-1, induced by TNF and IL-1, stimulate the chemotaxis of neutrophils, which are recruited 
to inflamed lung tissue (Kadioglu et al. 2000; Gauthier et al. 2007). Neutrophils recognize PAMPs on 
the surface of bacteria through PRRs and use surface Fc- and complement-receptors to bind bacteria 
opsonized by antibodies and complement components (Castellheim et al. 2009). The action of 
neutrophils is necessary to clear S. pneumoniae, achieved by phagocytosis and intracellular killing in 
phagosomes (Cohen 1994; Marriott & Dockrell 2007). This occurs via production of ROS, proteolytic 
enzymes, anti-microbial peptides, and acidification of the endosome (Castellheim et al. 2009). 
Neutrophils also bind and kill bacteria by neutrophil extracellular traps (NET), which consists of 
expelled histones, antimicrobial peptides, and enzymes bound to condensed DNA (Müller-Redetzky 
et al. 2014). 
If alveolar defense mechanisms are overwhelmed, invasion of S. pneumoniae into the bloodstream 
takes place. In the blood, several host proteins contribute to host defense including natural IgM 
antibodies, complement products, and pentraxins (Kadioglu & Andrew 2004; Shishido et al. 2012). 
Clearance of pneumococci from circulation strongly depends on opsonization, which enhances 
bacterial phagocytosis by leukocytes (Watson et al. 1993; Bogaert et al. 2004). 
Pentraxins are cytokine-inducible soluble pattern recognition receptors and part of the humoral 
innate immune system (Mantovani et al. 2008). They opsonize bacteria and promote phagocytosis by 
macrophages and neutrophils (Roy et al. 2002). They include the short pentraxins, C reactive protein 
(CRP) and serum amyloid P (SAP), as well as the long pentraxin PTX-3 (Doni et al. 2012). CRP is 
produced systemically in liver during the acute phase response, induced by IL-6 and IL-1. It binds to 
phosphorylcholine in the pneumococcal cell-wall, but also to C1q and Ficolin, which are opsonizing 
molecules of the classical and lectin activation pathway of the complement system (Suresh et al. 
2006). PTX-3 is produced locally in various cell types, with macrophages and neutrophils being the 
major sources. Like CRP, it interacts with components of the classical and lectin activation pathway of 
the complement system. PTX-3 recognizes and binds C1q, MBL, and Ficolin, and thereby amplifies 
effector functions of the complement system (Inforzato et al. 2013; Doni et al. 2012). 
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Figure 1.6: Complement cascades and their activators. The complement system is activated by three 
different pathways. The classical pathway is activated by IgM- or IgG-containing immune complexes, 
as well as CRP, SAP, and PTX-3 opsonized bacteria recognized by C1q, which activates C1s and C1r. 
The lectin pathway is activated by mannose-binding lectin motifs, exposed on bacteria, or by PTX-3 
and CRP opsonized bacteria, recognized by MBL or Ficolin, which activates MASP2. The alternative 
pathway is activated by C3b-coated pathogens. The three pathways converge at the generation of 
the C3 convertase that cleaves C3 to C3a and C3b. C3b is an opsonizing protein that coats pathogen 
surfaces to facilitate their uptake and destruction by phagocytes. C3b associate to C3 convertase 
forming the C5 convertase that cleaves C5 to C5a and C5b. C5b forms with C6, C7, C8, and C9 the 
membrane-attack complex that destroys certain pathogens by disrupting their membrane integrity 
(figure modified from Doni et al. 2012; Sarma & Ward 2011). 
 
The complement system is part of the humoral innate immune system and involves over 30 different 
membrane and serum proteins. It is initiated via three activation pathways (Figure 1.6). The classical 
pathway is activated by antibody binding to an antigen which is recognized by the collectin C1q. C1q 
is the opsonizing part of the C1 complex, which also comprises the proteases C1s and C1r. They are 
activated upon C1q binding and mediate complement activation. The lectin pathway is activated by 
the collectin mannose-binding lectin (MBL) or the Ficolin A or B, which recognize carbohydrates on 
microbial surfaces. Both MBL and Ficolin A circulate in serum as complex with MASP1/2. Binding of 
MBL or Ficolin A results in autoactivation of MASP2, which induces the complement activation 
cascade. The alternative complement pathway is continuously activated, but only amplified on 
foreign surfaces due to the absence of inhibitors such as factor B, factor D, and properdin, present on 
host cells (Gadjeva 2014; Sarma & Ward 2011). All the pathways converge at C3, which cleaves to 
C3a and C3b. The latter is an opsonizing protein that coats pathogen surfaces to facilitate their 
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uptake by phagocytosis. Moreover, C3 cleavage further results in the formation and activation of the 
membrane attack complex (C5b-9) (Gadjeva 2014; Sarma & Ward 2011).  
Animal experiments suggest that among all complement activation pathways the classical pathway 
dominantly protects against S. pneumoniae infection (Brown et al. 2002). However, it is also 
published that patients, homozygotes for an MBL codon variant, are highly susceptible to invasive 
pneumococcal infections (Roy et al. 2002). Regardless of the activation pathway, the main function of 
complement is the opsonization of pathogen surface structures facilitating phagocytosis, the 
activation of neutrophil chemotaxis, and the direct killing of the pathogen via formation of the 
membrane attack complex (Gadjeva 2014). 
 
1.3.  Aim of the thesis 
Recent data provide evidence for a crucial function of immunoproteasomes during an efficient 
immune response against invasive microorganisms. Numerous publications demonstrated the 
importance of immunoproteasomes for an effective immune reaction against viral infections for 
example Hepatitis B virus (HBV) (Robek et al. 2007), LCMV (Moebius et al. 2010), and IAV (Sibille et 
al. 1995). The role of immunoproteasomes in parasitic infections, including Toxoplasma gondii (Tu et 
al. 2009) and Trypanosoma cruzi (Chou et al. 2008), was discussed in several publications. A few 
studies investigated the function of immunoproteasomes in intracellular bacterial infections, 
including Listeria monocytogenes (Strehl et al. 2006) and Mycobacterium tuberculosis (Lv et al. 2011). 
So far, no data exists investigating the influence of immunoproteasomes on the progression of an 
extracellular bacterial infection.  
In this context, this project has been created to study whether immunoproteasome deficiency 
influences the course of an S. pneumoniae infection. To clarify the impact of immunoproteasomes on 
the innate immune response against S. pneumoniae, many different immunological parameters were 
analyzed with the focus on S. pneumoniae elimination. Therefore, several key questions were raised, 
which have been studied in 5i/LMP7-/- mice.  
 
- Does 5i/LMP7 deficiency influence the case and outcome of a pneumococcal pneumonia? 
- Is 5i/LMP7 essential for bacterial clearance? 
- Does 5i/LMP7 deficiency affect inflammation induced tissue damage? 
- Does 5i/LMP7 deficiency alter the cellular and humoral innate immune response, locally as 
well as systemically?  
- Is the composition of proteasomes changed during a S. pneumoniae infection? 
- Is there a link between proteasome composition, anti-bacterial cellular immune function, 
and disease progression?  
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These questions were addressed in vivo by using a mouse S. pneumoniae infection model. 
Additionally, ex vivo co-culture experiments with S. pneumoniae and primary leukocytes were 
performed to examine distinctive immunological cell functions. 
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2. Material and Methods 
 
2.1. Cell culture experiments 
All cell culture experiments were performed under sterile conditions. Cells were incubated at 37 °C 
and 5 % CO2. Primary cells were obtained from WT and 5i/LMP7
-/- C57BL/6 (J) mice. The protocol 
was approved by the Committee on the Ethics of Animal Experiments of Berlin State authorities 
(Permit Numbers: T371/11). 
 
Macrophage differentiation medium: RPMI, 10 % (v/v) FCS, P/S, 30 % (v/v) L929 supernatant 
Stimulation medium: RPMI, 10 % (v/v) FCS, 30 % (v/v) L929 supernatant, various stimuli 
Cultivation medium: RPMI, 10 % (v/v) FCS, P/S 
PBS: 140 mM NaCl, 9 mM Na2HPO4, 2.7 mM KCl, 1.5 mM KH2PO4, pH 7.2 
Detaching buffer: PBS, 5 mM EDTA 
Digestion buffer: RPMI, 600 g/ml collagenase A, 10 U/ml DNAse I 
MACS buffer: PBS, 0.5 % (w/v) BSA, 2 mM EDTA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1: Chemicals, reagents and kits used in cell culture experiments 
 
2.1.1. Cultivation of cell lines 
Cell lines were provided by Prof. Bastian Opitz (Medical Clinics of Charité Berlin with focus on 
Infectiology and Pneumology, Berlin, Germany) 
 
2.1.1.1. Cultivation of Raw264.7 cells 
Raw264.7 cells were cultivated in cultivation medium and splitted 1:10 every third day. It is an 
adherent murine macrophage like cell line, immortalized with Ebstein Barr Virus (EBV). 
 
 
Chemicals, Reagents, Kits  Supplier 
RPMI1640 Biochrom AG 
Fetal calf serum (FCS) Biochrom AG 
L-glutamine PAA Laboratories 
Penicillin/Streptomycin PAA Laboratories 
Gentamicin LONZA 
Collagenase A Roche 
Lipopolysaccharide (LPS) Sigma Aldrich 
mIFN Roche 
MG132 VWR International 
Chemicals, Reagents, Kits  Supplier 
Griess reagent kit Molecular Probes 
Apo One  Promega 
LDH Kit Roche 
CD45-MicroBeats Miltenyi 
MS-Columns Miltenyi 
EDTA Applichem 
Triton X Sigma 
Bovine serum albumin (BSA) Applichem 
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2.1.1.2. Cultivation of L929 cells 
L929 cells were cultivated in cultivation medium and split 1/10 every third day. It is an adherent 
murine fibroblast like cell line, constitutively expressing m-CSF. Its supernatant was used to generate 
bone marrow derived macrophages. Therefore, L929 cells were seeded on T175 cell culture flasks in 
100 ml medium. After they reached confluence, cells were cultivated for additional 10 days. The 
conditioned supernatant was sterile filtered, aliquoted, and stored at -80 °C.  
 
2.1.2.  Generation and cultivation of bone marrow derived macrophages (BMM) 
Mice were sacrificed by rapid cervical dislocation. The skin was peeled from each hind leg, which was 
cut off at the hip joint with scissors, leaving the femur and tibia intact. Excess muscles were removed 
and unopened bones sterilized with 70 % ethanol. Clean bones were opened on both ends and each 
bone cavity flushed with 5 ml cultivation medium. A single cell suspension was prepared by pushing 
the isolated bone marrow through a 70 m mesh. This cell suspension was centrifuged at 500 g for 
10 min at 4 °C, the pellet resuspended in 30 ml cultivation medium, and incubated over night by 37 
°C and 5 % CO2 in a cell culture dish. The next day, non-adherent cells, containing hematopoietic 
progenitor cells, were collected, centrifuged at 500 g and 4 °C for 10 min, and either processed 
further, or frozen in FCS with 10 % DMSO, and stored in liquid nitrogen.  
Bone marrow progenitor cells of one mouse were resuspended in 100 ml macrophage differentiation 
medium, distributed to 10 uncoated sterile plastic petri dishes, and cultivated for 9 days at 37 °C and 
5 % CO2. On day 5, another 10 ml fresh macrophage differentiation medium was added to each dish. 
On day 9, macrophages were fully differentiated, culture supernatant was discarded, and remaining 
adherent cells (> 90 % macrophages) were washed with pre-warmed PBS. Finally, macrophages were 
harvested by incubating adherent cells with detaching buffer for 5 min at 37 °C. These cells were 
centrifuged for 10 min at 500 g and 4 °C, resuspended in macrophage differentiation medium, and 
seeded on target cell culture dishes in order to perform further experimental procedures. 
 
2.1.3. Isolation of murine alveolar leukocytes 
First, lungs were flushed with 20 ml PBS by puncturing the right cardiac ventricle to remove blood 
leukocytes from lung tissue. White flushed lungs were isolated, minced, and digested for 60 min at 
37 °C in 5 ml digestion buffer. Later, a single cell suspension was prepared by pressing the lung 
homogenate through a 70 m cell strainer. After two washing steps with 30 ml PBS and 
centrifugation for 10 min at 500 g and 4 °C, CD45+ cells were enriched by magnetic isolation. This was 
performed according to the manufacturer’s protocol (MACS, Miltenyi). Shortly, the cell pellet was 
resuspended in 90 l MACS buffer and incubated with additional 10 l CD45 MicroBeads for 15 min 
at 4 °C. Afterwards, cells were washed by adding 20 ml MACS buffer, centrifuged at 500 g and 4 °C 
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for 10 min, resuspended in 500 l MACS buffer, and transferred to an MS column for positive 
isolation. Collected CD45+ cells were finally centrifuged at 500 g and 4 °C for 10min, resuspended in 
PBS, and processed in various experimental procedures. 
 
2.1.4. Stimulation of cells 
For ex vivo maturation or cytotoxicity assays 1x105, 3x105, 6x105, and 1x106 cells were seeded on 96, 
24, 12, and 6 well plate culture dishes on the eve of the experiment. The next day, cells were 
incubated with various stimuli in a total volume of 300 l, 500 l, 500 l, and 1 ml stimulation 
medium, respectively, for maximal 48h.  
Stimuli: 
 LPS (1 g/ml)  
 D39cps (MOI 10) 
 Heat inactivated D39cps (1/100)  
 mIFN (200 U/ml); alone and in combination with LPS or heat inactivated D39cps 
 Epoxomicin (250 nM): Cells were incubated with epoxomicin for 2h. Before additional 
stimulation, the inhibitor was removed and cells washed 3 times with PBS. 
 
2.1.5. Phagocytosis assay 
In order to characterize the phagocytosis efficiency of 5i/LMP7-/- phagocytes, alveolar leukocytes 
(5x105) were incubated with E.coli BioParticle-pHrodo (0.4 mg/ml) in 1 ml PBS and placed on ice for 
15 min to synchronize phagocytosis. Phagocytosis by leukocytes was started by incubating them at 
37 °C for 3h and stopped by cooling cells on ice. Negative control cells remained on ice. 
Subsequently, cells were stained with lineage antibodies and analyzed by flow cytometry (explained 
in section 2.4.1). Moreover, for a kinetic description 3x105 BMM were seeded on a 24 well plate 
culture dish on the eve of the experiment. The following day, medium was aspirated, cells washed 
and covered with PBS. In order to synchronize phagocytosis, macrophages were placed on ice for 15 
min. PBS was removed and cells covered with 100 l ice-cold PBS containing D39cps-PKH67 (MOI 
25). Except for the negative control cells, which remained on ice, macrophages were incubated at 37 
°C for up to 120min. Finally, to stop phagocytosis, cells were placed on ice, D39cps-PKH67 were 
removed, cells washed 3 times with ice-cold PBS, and harvested by scraping. The fluorescent 
intensity of internalized D39cps-PKH67 was measured by flow cytometry. 
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2.1.6. Gentamicin protection assay 
For the measurement of the intracellular early / late phase of killing, 6x105 / 1x106 BMMs were 
seeded on a 12 / 6 well plate culture dish. The following day, macrophages were co-cultivated with 
D39cps (MOI 10) in 500 l macrophage differentiation medium without antibiotics. This co-culture 
was incubated at 37 °C for 30 min / 4h to allow bacterial internalization. In order to remove 
remaining extracellular bacteria, cells were washed 3 times with pre-warmed PBS and cultivated 
further with macrophage differentiation medium, containing gentamicin (300 g/ml / 20 g/ml). 
After an incubation period of several hours, cells were washed with PBS and lysed by adding PBS with 
0.02 % Triton X. The supernatant, containing released bacteria, was diluted and plated on Columbia 
agar. Bacterial colonies were calculated after 9h incubation at 37 °C. 
 
2.1.7. Phagosome acidification assay 
For the determination of the phagolysosomal maturation efficiency, indicated by low pH values, 
macrophages were simultaneously incubated with E.coli BioParticles (0.4 mg/ml), which were labeled 
with a pH-sensitive fluorescent dye (pHrodo), and with heat inactivated D39cps (MOI 25), which 
were labeled with a pH-insensitive fluorescent dye (PKH67). The ratio of the fluorescent intensity of 
the pH-sensitive and the pH-insensitive reference dye is dependent on the pH and was determined 
by flow cytometry, and quantified by using a standard curve. On the eve of the experiment 3x105 
BMMs were seeded on a 24 well plate culture dish. The following day, cells were washed, covered 
with PBS, and placed on ice for 15 min, to synchronize phagocytosis. Subsequently, cells were 
covered with 100 l ice-cold PBS, containing both types of fluorescent labeled particles. Except for 
negative control cells, which remained on ice, macrophages were incubated at 37 °C for up to 120 
min. Acidification was stopped by placing cells on ice. Fluorescent labeled particles were removed 
and cells washed with ice-cold PBS. Concomitantly, a pH standard curve was created. Cells were 
incubated with E.coli BioParticles for 120 min and subsequently washed with ice-cold PBS to remove 
non-internalized BioParticles. Cells were incubated with pH-fixed PBS (2.5 to 8.1) for 10 min to allow 
permeabilization and equilibration of the phagosomal pH. Finally, cells were harvested by scraping 
and analyzed by flow cytometry.  
 
2.1.8. Indirect measurement of nitric oxide 
Nitrite (NO2
-) is a stable oxidative end-product of the molecule nitric oxide (NO). Its measurement is a 
quantitative indicator of nitric oxide production. On the eve of the experiment 1x105 BMM were 
seeded on a 96 well plate culture dish. The following day, macrophages were stimulated with LPS or 
heat inactivated D39cps. After an incubation period of maximal 48h, conditioned medium was 
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collected and its nitrite content determined, using the Griess Reagent kit for nitrite determination, 
according to the manufacturer’s protocol (Molecular Probes).  
 
2.1.9. Measurement of apoptosis and necrosis 
Apoptosis was measured with an Apo-ONE Homogeneous Caspase 3/7 Assay, obtained by Promega. 
The amount of necrosis was determined by using the Cytotoxicity Detection Kit, provided by Roche. 
These assays were performed in 96 well plate dishes according to the manufacturer’s instructions. 
Thereby, on the eve of the experiment 1x105 BMM were seeded on a 96 well plate culture dish. The 
following day, macrophages were co-cultivated with D39cps for 4h. As positive control, cells were 
incubated with 10 M MG132 for 24h.  
 
2.2. Microbiological methods 
All microbiological experiments were performed under sterile conditions (Gentechnik 
Sicherheitsstufe S2). Bacteria were incubated at 37 °C and 5 % CO2. 
 
THY medium: 30 % (w/v) Todd-Hewitt-Bouillion, 5 % (w/v) Yeast 
PBS: 140 mM NaCl, 9 mM Na2HPO4, 2.7 mM KCl, 1.5 mM H2PO4, pH 7.2 
 
 
 
 
 
 
Table 2.2: Chemicals, reagents, kits, and instruments used in microbiological experiments 
 
2.2.1. Streptococcus pneumoniae 
D39cps: This bacterium belongs to the bacterial strain Streptococcus pneumoniae serotype 2. It 
carries a deletion mutation in its capsule gene which was generated by homologous recombination 
with a canamycin cassette, performed by AG Hammerschmidt (University Greifswald, Department of 
Genetics of Microorganisms, Germany). The working glycerol stock was provided by Dr. Janine 
Zahlten; AG Hippenstiel (Medical Clinics of Charité Berlin, with focus on Infectiology and 
Pneumology, Berlin, Germany) and stored at -80°C. This strain was used in cell culture experiments. 
 
PN36: This bacterium belongs to the bacterial strain Streptococcus pneumoniae serotype 3. It is a 
mouse adapted strain. The working glycerol stock was provided by Dr. Katrin Reppe; AG Witzenrath 
Chemicals, Reagents Supplier 
Todd-Hewitt-Bouillion BD 
Columbia agar (5 % sheep blood) BD 
Yeast extract  BD 
Canamycin Calbiochem 
Fetal calf serum (FCS) Biochrom AG 
Kits Supplier 
PKH67 linker kit Sigma 
pHrodo E.coli BioParticle Molecular probes 
  
Instruments Supplier 
Photometer Genesys 20 Thermo Scientific 
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(Medical Clinics of Charité Berlin, with focus on Infectiology and Pneumology, Berlin, Germany) and 
stored at -80°C. This strain was used to induce pneumonia in in vivo experiments. 
 
2.2.2. Cultivation of D39cps for in vitro co-cultivation experiments 
Bacteria, obtained from the glycerol stock with a sterile inoculating loop, were plated on Columbia 
agar and grown for 10h – 12h at 37 °C and 5 % CO2. Single colonies were transferred to 20 ml THY 
with 10 % FCS. This suspension was incubated for 4h – 5h at 37 °C until it reached an OD600 of 0.2 – 
0.4, which corresponds with the early middle log growth phase, containing bacteria being most vital. 
An adequate volume of this suspension was transferred to an eppendorf tube and centrifuged at 
4000 g for 5 min. The THY with 10 % FCS was discarded and bacteria resuspended in an equal volume 
of RPMI with 10 % FCS. An OD600 of 0.1 corresponds with 10
8 cfu/ml.  
 
2.2.3. Cultivation of PN36 for in vivo infection experiments 
Bacteria, obtained from the glycerol stock with a sterile inoculating loop, were plated on Columbia 
agar and grown for 9h at 37 °C and 5 % CO2. Single colonies were transferred with a cotton bud to 20 
ml THY with 10 % FCS until reaching an initial OD600 of 0.03 – 0.04. This suspension was incubated for 
2h at 37 °C until it grew to an OD600 of 0.3 – 0.4, which corresponds with the early middle log growth 
phase, containing bacteria being most vital. It was centrifuged at 4000 g for 10 min, without brake. 
The THY with 10 % FCS was discarded and bacteria resuspended in PBS (1x109 cfu/ml). This 
suspension was further diluted in PBS, depending on the experiment. An OD600 of 0.1 corresponds 
with 108 cfu/ml. 
 
2.2.4. Generation of heat inactivated D39cps  
Bacteria were grown in 50 ml THY with 10 % FCS to an OD600 of 0.6 – 0.7. This suspension was 
centrifuged at 4000 g for 10 min, THY medium discarded, and bacteria washed by adding 5 ml PBS. 
This bacterium solution was heat inactivated for 20 min at 60 °C. An OD600 of 0.1 is defined as 10
8 
particles/ml. The heat inactivated D39cps solution was adjusted to an OD600 of 5.0, aliquoted, and 
stored at -20 °C.  
 
2.2.5. Generation of fluorescent labeled D39cps 
PKH67 is a fluorescent dye that intercalates in lipid double layer membranes. Heat inactivated 
D39cps were fluorescent labeled using the PKH67 green fluorescent cell linker mini kit according to 
manufacturer’s (Sigma) protocol. Finally, the OD600 was determined, the lysate aliquoted, and stored 
at -20 °C. (An OD600 of 0.1 is defined as 10
8 particles/ml) 
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2.2.6. Generation of fluorescent labeled E.coli BioParticle conjugates  
A solution of pHrodo E.coli BioParticle conjugates was prepared by resuspending an aliquot (2 mg) in 
PBS. This solution was strongly vortexed and sonicated for 5 min for proper homogenization 
(Molecular probes; Life technologies). 
 
2.3. Animal infection experiments 
All animal experimental protocols were approved by the Committee on the Ethics of Animal 
Experiments of Berlin State authorities (Permit Numbers: G0073/11). The S. pneumoniae mouse 
infection model was established by AG Witzenrath (Medical Clinics of Charité Berlin, with focus on 
Infectiology and Pneumology, Berlin, Germany). Experimental procedures were supervised by Dr. 
Katrin Reppe. All analyzed groups contained only female littermates with an age of 8-11 weeks. 
 
Ulmer-Mix: 3 ml 100 mg/ml Ketamin, 2.4 ml Rompun 2 %, 3 ml NaCl 0.9 %  
Narcosis-Mix: 2 ml 100 mg/ml Ketamin, 1 ml Rompun 2 %; 9 ml NaCl 0.9 % 
Heparin-Mix: NaCl 0.9 % + Heparin (5000 IE/ml) in equal volumes 
S. peumoniae solution: Hyaluronidase + S. pneumoniae in PBS in equal volumes 
Digestion buffer: RPMI + 2 mg/ml collagenase II + 0.3 mg/ml DNAse I  
PBS: 140 mM NaCl, 9 mM Na2HPO4, 2.7 mM KCl, 1.5 mM KH2PO4, pH 7.2 
BAL-Solution: PBS, Complete, 0.1 % (w/v) BSA 
 
 
Table 2.3: Reagents, kits, and instruments used in animal experiments 
 
2.3.1. Mouse breeding 
C57BL/6 (J) N6 5i/LMP7-/- mice were generated by Ulrich Steinhoff  and Hans Jörg Fehling (Fehling et 
al. 1994) and housed in FEM Bayer Unit 4. Mice were kept at the animal facilities of the Charité, 
University Medical Center, according to the European and Berlin State guidelines for animal welfare. 
Mice were bred in a heterozygous mating. Their genotype was determined by PCR analysis on 
genomic DNA, obtained from tail-biopsies.  
 
 
Chemicals, Reagents Supplier 
Ketamin Cp pharma 
Rompun Cp pharma 
NaCl solution 0.9 % Braun 
Hyaluronidase Roche 
Collagenase II Roche 
DNAse I Roche 
Reagents, Kits Supplier 
Anti-5i/LMP7 abcam 
BSA Sigma 
Heparin  Ratiopharm 
EDTA Tubes Sarstedt 
Paraformaldehyd Sigma 
Erytrocyte. lysis b. BD 
Instruments Supplier 
Labor scale G & G 
Recal thermometer 
Bat12 
Physitemp 
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2.3.2. Infection of mice 
Animals were intranasally infected with PN36. Therefore, mice were anesthetized by a peritoneal 
application of 50 – 60 l Ulmer-Mix. Animal’s reflexes were tested and sedated mice hanged at their 
incisors. Subsequently, 10 l of S. pneumoniae solution or PBS, as negative control, was applied on 
each nostril. Afterwards, sedated and infected mice were returned to their cages and exposed to red 
light for 1h. Mice, which inhaled the liquid, containing S. pneumoniae, established clinical signs of a 
pneumonia. Medical conditions of infected mice were monitored and documented every 12h. 
Thereby, the grade of activity, changes in breathing, in social behavior, and in drinking and food 
behavior was assessed. Furthermore, body temperature and body weight was determined, using a 
rectal thermometer and a labor scale. For every bacterial charge a dilution serious was plated on 
Columbia agar in order to control the amount of employed bacteria.  
 
2.3.3. Preparation of mice 
Mice were narcotized by a peritoneal application of 250 – 300 l Narcosis-Mix. Animal’s pain reflexes 
were tested, narcotized mice fixated, and dissected. Therefore, a median skin incision was performed 
from the abdomen to the mandibula. The muscle around the trachea was removed to get access to 
the trachea, which was ligated, if necessary. Afterwards, the peritoneum was opened till the Xyphoid. 
Heparin-Mix (50 l) was applied through the diaphragm into the right cardiac ventricle. Blood was 
taken via the inferior vena cava by which mice bleed to death. Diaphragm was removed and the 
thorax disclosed. Lung was flushed with 20 ml PBS by puncturing the right cardiac ventricle. Lung 
tissue was dissected without bronchus and further processed. In some experiments other organs, 
such as liver, were removed and further analyzed. 
 
2.3.4. Analysis of the cellular immune status 
In order assess the amount of various different leukocytes upon infection in lung as well as in 
circulation, mice infected with 5x106 cfu were sacrificed at 6h, 24h, and 48h of infection. Lungs were 
flushed and dissected without bronchus. Lungs were minced and digested in 6 ml digestion buffer for 
30 min at 37 °C. A single cell suspension was prepared by pressing the lung homogenate through a 70 
m cell strainer. It was centrifuged for 10 min at 500 g and 4 °C. Lung cells were resuspended in 2 ml 
erythrocyte lysis buffer and incubated for 10 min at 4 °C. This reaction was stopped by adding 30 ml 
PBS. Cells were centrifuged for 10 min at 500 g and 4 °C, resuspended in 3 ml PBS, distributed to 
eppendorf tubes, and stained for flow cytometry. The total leukocyte amount per lung was 
determined by adding Trucount beads. FACS Calibur was used for the analysis of lungs obtained from 
mice infected for 48h. For the analysis of the cellular immune status of the lungs, obtained from mice 
at 6h and 24h of infection, the same lung preparation protocol was employed, but for the flow 
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cytometry a FACS Canton was used, kindly provided by AG Hackstein (Justus-Liebig-University 
Gießen; Centre of Transfusion Medicine and Hematotherapy). 
Leukocyte distribution in venous EDTA blood, obtained from infected animals via the inferior vena 
cava, was assessed by flow cytometry, using Trucount beads and a FACS Calibur. 
 
2.3.5. Determination of bacterial burden 
Mice infected with 5x106 cfu were sacrificed 24h and 48h post infection. Lungs were dissected 
without bronchus and minced by pressing the tissue through a 100 m cell strainer. The lung 
homogenate was collected in a 50 ml Falcon tube, the cell strainer washed with PBS, and the volume 
of the tissue solution adjusted to 20 ml by adding PBS. An aliquot (10 l) of this solution and of a 
dilution series (1/10 -> 1/10.000 in PBS) was plated on Columbia agar which was incubated at 37 °C 
for 9h. The quantity of bacteria was calculated by counting the cfu´s. Likewise, bacterial burden in 
blood was assessed by plating 10 l venous EDTA blood (pure -> 1/10.000 in PBS) on Columbia agar 
which was incubated at 37 °C for 9h and quantified by counting cfu´s. 
 
2.3.6. Study of the approximate survival rate  
Mice were infected with 7.5x104 cfu and monitored for 10 days. Their medical condition was 
documented every 12h. When the disease developed a severe state without possibility of physical 
recovery, and when it was conceivable that infected mice suffer sickness and pain which were not 
ethical, mice were euthanized by an intraperitoneal application of 300 l Narcosis-Mix. The state of 
disease was measured by the means of a score sheet for “human endpoints”. This score sheet 
comprises guidelines for the clinical assessment of infected animals. These guidelines were provided 
by LAGESO. („Empfehlungen des Arbeitskreises Berliner Tierschutzbeauftragter für die vorzeitige 
Tötung erheblich leidender Versuchstiere“ [Stand 22.07.2009]) 
 
2.3.7. Histological analysis of infected lung tissue 
Mice were infected with 5x106 and 1x106 cfu and sacrificed at 24h and 48h, respectively, of infection. 
In order to remove the whole respiratory tract, the trachea was ligated and cut above the larynx. The 
trachea, bronchus, and lung were dissected in one piece and fixated in 3.7 % paraformaldehyd for 
24h – 48h. Fixated tissue was further processed at the Institute of Animal Pathology, FU Berlin. 
Hematoxylineosin (HE) staining and immune detection of 5i/LMP7 expression was carried out by Dr. 
Olivia Kershaw (AG Gruber, FU Berlin, Department of Veterinary Pathology, Berlin, Germany). 
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2.3.8. Processing of a bronchial alveolar lavage (BAL) 
Mice infected with 5x106 cfu were sacrificed 48h post infection. After flushing the lung with 20 ml 
PBS by puncturing the right cardiac ventricle, the uncovered trachea was punctured with a cannula. 
The trachea and the cannula were ligated. BAL-solution (800 l) was infused in and immediately 
aspirated off the lung. Recovered BAL fluid was centrifuged at 1200 g for 10 min, cell free liquid 
frozen in liquid nitrogen, and stored at -80 °C until it was analyzed using immunological methods. 
 
2.4. Immunological methods  
PBS: 140 mM NaCl, 9 mM Na2HPO4, 2.7 mM KCl, 1.5 mM KH2PO4, pH 7.2  
FACS buffer: PBS, 0.05 % (v/v) FCS, 2 mM EDTA 
 
 
Table 2.4: Instruments, kits, and software used in immunological experiments 
 
2.4.1. Flow cytometry  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5: Antibodies used in flow cytometry 
 
For flow cytometry 2.5x105 cells were distributed to a 96 well plate in a total volume of 100 l FACS 
buffer. Specific antibodies (1/100) were added and incubated in the dark at 4 °C for 30 min. 
Afterwards, cells were washed twice with 150 l FACS buffer and centrifuged at 500 g and 4 °C for 5 
min. Finally, cells were resuspended in 200 l – 500 l FACS buffer and analyzed. 
 
 
Kits Supplier 
Trucount BD 
albumin ELISA  Bethyl 
Bio-Plex Pro mouse Assay BioRad 
  
Software Supplier 
Cell Quest Pro BD 
FlowJo FlowJo 
BioPlex BioRad 
  
Instruments Supplier 
FACS Calibur BD 
FACS Canton BD 
Photometer SynergyHT 
Bio-Plex working station BioRad 
Antibody Fluorochrom Supplier 
CD86 PE BioLegend 
CD45 APC-Cy7 BD 
CD45  PerCP-Cy5.5 BD 
CD25 Pacific Blue BD 
F4/80 Pacific Blue BD 
F4/80 APC BioLegend 
Gr1 APC BD 
Gr1  PE BD 
CD11c FITC BD 
CD11c PE-Cy7 BD 
Antibody Fluorochrom Supplier 
NK1.1 PE-CF594 BD 
NK1.1 PE BD 
CD19  PerCP-Cy5.5 BD 
CD19  APC BD 
CD3e  PE BioLegend 
CD3e FITC BD 
TCR g/d  FITC Biolegend 
CD8a APC Biolegend 
CD4 PE-Cy7 BD 
Siglec-F PE BioLegend 
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Table 2.6: Antibody panels for cell discrimination by flow cytometry  
 
2.4.2. Trucount  
The cell number in 1 lung or 1 l blood was assessed by spiking samples with Trucount beads. 
Therefore, 50 l blood or 100 l cell suspension, together with specific FACS antibodies, were added 
to a Trucount tube (BD), vortexed intensely, and incubated for 30 min at room temperature. 
Erythrocytes were lysed by adding 450 l or 400 l erythrocyte lysis buffer, respectively. Afterwards, 
without any further washing step, Trucount suspension was vortexed, transferred to a FACS tube, 
and analyzed by flow cytometry, using a FACS Calibur or FACS Canton. 
 
Calculation - lung leukocytes: 
(CD45+ cells x total beads in tube x total volume of cell suspension) / (beads x analyzed volume) 
Calculation – blood leukocytes: 
(CD45+ cells x total beads in tube) / (beads x volume of blood sample) 
 
2.4.3. Elisa 
The amount of serum albumin in plasma and in BAL fluid was measured by ELISA (Bethyl). Therefore, 
collected BAL fluid was diluted 1/10.000 and 1/20.000, plasma was diluted 1/750.000 in blocking 
buffer, and analyzed according to the manufacturer’s instructions. 
 
Coating buffer: 0.1 M sodium carbonate pH 9.5  
Washing buffer: PBS, 0.05 % (v/v) Tween-20  
Blocking buffer: PBS, 10 % (v/v) FCS 
Stopping solution: 1 M H3PO4 
 
2.4.4. Multi-plex analysis 
Cytokine and chemokine concentrations in plasma and BAL fluids of infected mice were measured by 
using the Bio-Plex Pro Mouse Cytokine Group I Assay and the multiplex working station, provided by 
Cell Type Lineage marker 
Leukocytes CD45
+
                                                                   
Mph CD45
+
, Siglec F
+
, F4/80
+
                                           
DC CD45
+
, Siglec F
-
, CD11c
+
  
Granulocytes CD45
+
, Gr1
+
 
B-cells CD45
+
, CD19
+
 
NK-cells CD45
+
, NK1.1
+
 
Cell Type Lineage marker 
T-cells CD45
+
, CD3
+
 
T-helper CD45
+
, CD3
+
, CD4
+
 
T-cytotox CD45
+
, CD3
+
, CD8
+
 
T-reg CD45
+
, CD3
+
, CD25
+
 
T- CD45
+
, CD3
+
, TCR g/d 
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the Deutsches Rheuma-Forschungszentrum (DRFZ) Berlin. Therefore, pure BAL fluid and plasma, 
diluted ¼, was processed according to manufacturer’s protocol (BioRad). 
 
2.4.5. Serological Analysis 
The enzyme activity of ALAT and LDH in serum of ill animals was measured by the Institute of 
Veterinary Medicine and Diagnostics, Berlin. 
 
2.5. Molecular methods  
6 x DNA sample buffer: 50 % (v/v) glycerine, 50 mM EDTA, 0.25 % (w/v) bromophenol blue 
TAE buffer: 40 mM Tris, 1 mM EDTA, 20 mM acetic acid  
Tissue digestion buffer: 100 mM Tris, 200 mM NaCl, 5 mM EDTA, 0.2 % (w/v) SDS, 200 g/ml 
proteinase K 
 
 
Table 2.7: Reagents, kits, and instruments used in molecular biological assays 
 
2.5.1. Isolation of genomic DNA 
Tail biopsies were lysed with tissue digestion buffer over night at 55 °C. Undigested tissue was 
pelletized at 13000 g for 10 min and supernatant, containing genomic DNA, transferred to a new 
eppendorf tube. The DNA was precipitated by adding an equal volume of isopropanol. The eppendorf 
tube was inverted several times and centrifuged at 13000 g for 15 min. Supernatant was discarded 
and the DNA pellet washed with 70 % ethanol. This was centrifuged for 10 min at 13000 g, the 
supernatant discarded, and the remaining ethanol evaporated. The genomic DNA was dissolved in 
aqua bidest. and stored at 4 °C until analysis.  
 
2.5.2. PCR and agarose gel electrophoresis 
AppliTaq DNA PCR System together with primers was applied according to the manufacturer’s 
instructions (Applied Biosystems). The PCR program was employed as described below. The PCR 
Chemicals , Kits Supplier 
Taq Polymerase kit Applichem 
cDNA Synthesis kit Roche 
Real Time Mastermix Applied Biosystems 
Proteinase K Sigma 
PCR-Primer Biotez 
SYBR® safe DNA gel stain Invitrogen 
Agarose Serva 
Trizol Invitrogen 
  
Instruments Supplier 
Thermocycler Gradient Eppendorf 
Rotor Gene 3000 Corbett Research 
MP-FastPrep24  MP-Biomedicals 
NanoDrop 1000 Peqlab 
Gel – Visualizer Syngene 
  
Software Supplier 
Rotor Gene Monitor 4.6 Corbett Research 
PCR Visual Gene Snap 
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products were supplemented with 10 x DNA-sample buffer and separated electrophoretically on 1 % 
agarose gels. Gels were stained with SYBR® safe DNA gel stain and visualized under UV light.  
 
Primer sequence: 
 LMP7 wild type allele (600 bp) 
LMP7 Fw: GGA CCA GGA CTT TAC TAC GTA GAT G 
LMP7 Rev: CTT GTA CAG CAG GTC ACT GAC ATC G 
 LMP7 knock-out allele (700 bp) 
Neo Fw: CCG ACG GCG AGG ATC TCG TCG TGA 
LMP7 Rev: CTT GTA CAG CAG GTC ACT GAC ATC G 
 
PCR Program:  
7 min 95 °C DNA denaturation  
32 cycles  30 sec 94 °C  
30 sec 63 °C primer annealing  
45 sec 72 °C DNA polymerization  
7 min 72 °C 
∞ 4 °C  
 
2.5.3. Isolation of RNA  
Tissue or pelletized cells, incubated in 1 ml Trizol, was disintegrated using a shredding machine. After 
adding 200 l chloroform, it was thoroughly mixed by shaking, incubated at room temperature for 3 
min, and centrifuged at 13000 g for 20 min at 4°C. The upper liquid phase, containing the RNA, was 
transferred into a new eppendorf tube. After adding 500 l isopropanol, RNA was precipitated at 
room temperature for 20 min and pelletized at 13000 g for 20 min at 4 °C. The supernatant was 
discarded, the RNA washed with 1 ml 70 % ethanol, and centrifuged at 13000 g for 10 min at 4 °C. 
The supernatant was removed, the RNA dissolved in 300 l aqua bidest., and stored at -80 °C. RNA 
concentration was measured using the NanoDrop 1000.  
 
2.5.4. cDNA synthesis  
Transcription of mRNA into cDNA was performed by using the cDNA generation kit (Roche). 
Therefore, RNA (1 g), Oligo-Td primer and aqua bidest. was added and annealed for 10 min at 70 °C. 
Afterwards reaction buffer, containing reverse transcriptase, was added and reverse transcription 
carried out at 37 °C for 60 min using a PCR cycler, according to the manufacturer’s instructions.  
 
2.5.5. Real Time PCR / TaqMan® 
The reaction mix was prepared by adding 1 l cDNA to 9 l reaction buffer, containing 1 l TaqMan 
primer, 3 l aqua bidest. and 5 l mastermix (2 x). The TaqMan® PCR was performed in duplicates, 
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using the Rotor gene 3000 cycler. Gene expression was analyzed with the Rotor Gene Monitor 4.6 
software and normalized to the housekeeping gene HPRT1 by means of the ΔΔCt method. 
 
      Real Time PCR Program: 
     10 min 95 °C DNA denaturation  
      40 cycles     15 sec 94 °C  
             30 sec 60 °C primer annealing  
             60 sec 60 °C DNA polymerization 
 
 
 
 
Table 2.8: TaqMan primer 
 
2.6. Biochemical methods  
 
 
 
 
 
 
 
 
 
 
 
Table 2.9: Chemicals, reagents, kits, and instruments used in biochemical experiments 
 
RIPA buffer: 50 mM Tris-HCl, 150 mM NaCl, 1 % (v/v) Nonidet P40, 0.5 % Sodium-deoxycholate, 0.1 
% (w/v) SDS and 1x Complete 
TEAD buffer: 20 mM Tris-HCl, 1 mM EDTA, 1 mM NaN3, 1 mM DTT, pH 7 
10 x SDS-Running buffer: 250 mM Tris-HCl pH 8.8, 2 M glycine, 1 % (w/v) SDS 
Blotting buffer: 25 mM Tris-HCl, 200 mM glycine, 25 % (v/v) methanol  
Blocking solution: PBS, 0.5 % (v/v) Tween-20, 10 % (v/v) RotiBlock 
Washing buffer: PBS, 0.5 % (v/v) Tween-20  
4 x stacking gel buffer: 0.5 M Tris-HCl pH 6.8, 0.4 % (w/v) SDS  
4 x separating gel buffer: 1.5 M Tris-HCl pH 6.8, 0.4 % (w/v) SDS  
10 x SDS-sample buffer: 500 mM Tris-HCl pH 6.8, 60 % (v/v) glycerol, 20 % (w/v) SDS, 1 M DTT, 1% 
(w/v) bromophenol blue  
Real-Time Primer Supplier 
Hprt (Mm01545399_m1) Applied Biosystems 
Saa1 (Mm00656927_g1) Applied Biosystems 
Mbl2 (Mm0087623_m1) Applied Biosystems 
Sfltpa (Mm00484287_m1) Applied Biosystems 
Sftpd (Mm00486060_m1) Applied Biosystems 
C1qa (Mm00432142) Applied Biosystems  
Ptx3 (Mm00477268_m1) Applied Biosystems 
Fcna (Mm00484287_m1) Applied Biosystems 
Il1b (Mm00434228_m1) Applied Biosystems 
Chemicals, Kits Supplier 
Acrylamide Applichem 
APS Applichem 
TEMED Biomol 
  
Chemicals, Reagents, Kits Supplier 
Prestained Protein Ladder Fermentas 
Nitrocellulose membrane Immobilon Millipore 
ECL Plus WB Detection Reagents GE Healthcare 
Film X-OMAT UV Kodak 
Complete Inhibitor Mix Roche 
RotiBlock Roth 
Coomassie Serva 
Fluorogenic substrates Bachem 
Epoxomicin Calbiochem 
BCA-protein Assay Kit Thermo Fisher Scientific 
Instruments Supplier 
Electrophoresis 
chamber BioRad 
Blotting chamber BioRad 
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Separating polyacrylamide gel (12.5 %): 15 ml 30 % acrylamide, 12 ml H2O, 9 ml 4 x separating gel 
buffer, 25 l TEMED, 300 l 10 % (v/v) APS 
Stacking polyacrylamide gel (5 %): 4.5 ml 30 % acrylamide, 10.5 ml H2O, 7.5 ml 4 x stacking gel 
buffer, 30 l TEMED, 300 l 10 % (v/v) APS 
Coomassie staining solution: 0.1 % (w/v) coomassie, 30 % (v/v) methanol, 10 % (v/v) acetic acid, 60 
% (v/v) aqua bidest. 
Coomassie destaining solution: 30 % (v/v) methanol, 10 % (v/v) acetic acid, 60 % (v/v) aqua bidest. 
 
2.6.1. Protein isolation and quantification 
Cells were harvested, washed with 1 ml PBS, and centrifuged at 8000 g for 2 min at 4 °C. Under 
denaturizing conditions, the cell pellet was lysed with 50 – 70 l RIPA buffer, carried out for 1h on ice 
with occasional vortexing. Under native conditions, cell pellets were resuspended in 50 – 70 l TEAD 
buffer, organs pestle in 200 l TAED buffer and lysed by subsequent 3 cycles of freeze and thaw in 
liquid nitrogen. In order to separate lysate from cell debris, it was centrifuged at 13000 g for 15 min 
at 4 °C. The supernatant was collected and stored at -80 °C, or processed immediately. The protein 
concentration was determined with the BCA protein assay kit, according to manufacture´s 
instructions in 96 well plates. 
 
2.6.2. SDS-PAGE, western blotting and immuno-detection 
For separation of proteins under denaturating conditions, SDS-polyacrylamide gel electrophoresis 
was performed. Therefore, cell lysate was diluted in SDS-sample buffer to a final protein 
concentration of 1 g/l and denaturated at 95 °C for 5 min. Subsequently, 10 – 20 g total lysate 
was loaded onto a 12.5 % SDS-polyacrylamide gel. The electrophoresis was performed at 120 V for 1 
– 2h. The protein marker, PageRuler prestained protein ladder, was used as standard to estimate the 
molecular weight of separated protein bands. These proteins were transferred to a nitrocellulose 
membrane by using the Wet blot procedure and an appropriate blotting buffer. It was performed at 
a constant electric current of 4000 mA for 1h. Thereafter, free binding sites of the membrane were 
saturated with a blocking solution at room temperature for 1h. The incubation with the primary 
antibody against the antigen of interest was performed at 4 °C over night. The next day, the 
membrane was washed 3 times for 10 min in washing buffer, followed by incubation with the 
appropriate secondary antibody at room temperature for 1h. It targets an antigen from the first 
antibody and was diluted in blocking solution. Finally, the membrane was washed 3 times for 10 min 
in washing buffer. For visualization, horseradish peroxidase (HRP)-labeled secondary antibodies and 
ECL Plus™ Western Blotting Detection Reagent was used. The chemoluminescence signal was 
detected on autoradiography film X-OMAT UV. 
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Table 2.10: Antibodies used in western-blot 
 
2.6.3. 20S purification 
The 20S proteasome purification from differentiated BMM was performed by Alexander Kloß. 
Therefore, 1x109 BMM were pestled in TEAD buffer, using a douncer, and centrifuged for 60 min at 
13000 g and 4 °C. The resulting supernatant was used for the determination of the protein content, 
as well as for the purification of 20S proteasomes, as described in Schmidt et al. 2006. Briefly, this 
consists of the following steps: a fractionated protein precipitation with ammonium sulphate, 
chromatography on DEAE-Sephacel, gel filtration on Superose 6, and anion exchange 
chromatography on Mono Q. After purification of the 20S proteasome it was further processed for 
2D gel electrophoresis.  
 
2.6.4. 2D Gel analysis 
The purified 20S proteasome (25 g) was precipitated in ethanol (96 %) by incubating it in a 2.5 fold 
volume of ethanol over night at -20 °C. Precipitated 20S proteasomes were centrifuged for 60 min at 
13000 g and 4°C, and its pellet washed (2 x) with 1 ml ethanol (70 %). The proteasomes were 
centrifuged again for 30 min at 13000 g and 4 °C, its pellet dried, and sent to Protalys GmbH, which 
performed the 2D electrophoresis. 
 
2.7. Statistics 
The statistical significance was determined by using the Mann-Whitney U Test for in vivo data and by 
using the Student t-test for in vitro generated data. All statistical analyses were performed using 
GraphPad Prism Software (version 4.03) (GraphPad, San Diego, CA, USA). Statistical significance was 
achieved when p<0.05; *p<0.05, **p<0.01, ***p<0.001. 
Antibodies Supplier 
anti-5i/LMP7 abcam 
anti-5 abcam 
anti-1i/LMP2 abcam 
anti-1 Self-made 
anti-2i/MECL-1 Self-made 
anti-4 Self-made 
anti-IB Santa Cruz 
anti-Actin Cell signaling 
Antibodies Supplier 
anti-p-cFos  Cell signaling 
anti-cFos Cell signaling 
anti-p-cJun Cell signalling 
anti-cJun Santa Cruz 
anti-p-ATF2 Cell signalling 
anti-ATF2 Cell signalling 
anti-rabbit-HRP Dianova 
anti-mouse-HRP Seramun 
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3. Results 
Since pathogenesis of pneumococcal pneumonia is a complex interplay between virulence and host 
immunity (van der Poll & Opal 2009), we analyzed the role of immunoproteasomes, contributed by 
the host, in preservation of immunological cell function and pathogen elimination during the innate 
immune response against S. pneumoniae. 
Therefore, we investigated the involvement of the immuno-subunit β5i/LMP7 in antibacterial 
defense mechanisms of the innate immune system by using a murine infection model. In order to 
characterize microbiological, physiological, and immunological effects of pneumococcal pneumonia 
in β5i/LMP7-/- mice, we documented resulting histopathological tissue damage, leukocyte 
recruitment, leukocyte function, cytokine and chemokine release, expression of opsonizing 
molecules, bacterial clearance, and survival of infected animals. Furthermore, we analyzed 
immunoproteasome expression in pulmonary and peripheral tissue as well as leukocytes, and 
assessed its contribution towards an efficient immune reaction. 
 
3.1. 5i/LMP7 deficiency aggravates the clinical signs of pneumococcal pneumonia 
By illustrating the role of immunoproteasomes in the host defense during S. pneumoniae infection, 
we examined the impact of β5i/LMP7 deficiency on the clinical case of a pneumococcal pneumonia. 
Progression of pneumonia is manifested in a variety of clinical signs such as short breathing, scrubby 
fur, apathy but also loss in body weight and body temperature (Mizgerd & Skerrett 2008).  
Infected animals seemed to recover for a while but then developed a gradually pronounced 
hypodynamic state which was associated with a gradual loss in body weight and body temperature 
from 24h to 48h of infection (Figure 3.1A). By applying an infectious dose of 5x106 PN36/mouse, mice 
usually died short after 48h of infection and were therefore euthanized before reaching this 
endpoint. Nevertheless, the loss in body weight was significantly stronger in β5i/LMP7-/- compared to 
WT mice. While WT mice lost about 15.1 % of their initial body weight β5i/LMP7-/- mice lost about 
18.7 % of their initial body weight 48h post infection. This effect was confirmed by documenting the 
drop in body temperature of ill animals. While the body temperature of β5i/LMP7-/- mice significantly 
decreased by a median of 2.1 °C, the body temperature of WT mice hardly fell between 24h und 48h 
of infection.  
Clinical diagnostic parameters such as expression of acute phase proteins help to assess the severity 
of infection. Serum amyloid A (saa1) is an acute-phase protein which is expressed in liver in response 
to inflammation. It is used as marker of inflammation in clinical pathologies and correlates with the 
severity of infection (Yamada 1999). Therefore, its liver expression was determined 6h, 24h, and 48h 
post infection (Figure 3.1C). The expression of saa1 started at 24h of infection and increased further 
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during the late phase of pneumonia, in both mouse strains, but significantly stronger and only 
significant in β5i/LMP7-/- mice. Between 24h und 48h of infection, the expression of saa1 increased in 
β5i/LMP7-/- mice from about 1.8x105 to about 4.4x105 while in WT mice it elevated from about 
1.2x105 to about 1.9x105.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: β5i/LMP7-/- mice suffer from a more severe case of pneumonia. (A) Monitoring of body 
weight and body temperature 24h and 48h after intranasal application of 5x106 PN36/mouse (each 
group with n= 12 – 29) (B) Assessment of the approximate survival rate for up to 10 days upon 
intranasal application of 7.5x104 PN36/mouse (each group with n= 17). (C) Analysis of mRNA 
expression of the acute phase protein SAA in liver after intranasal application of 5x106 PN36/mouse, 
performed by RT and Real Time PCR (each group with n= 3 - 14). In all experiments, 20 l PBS/mouse 
was intranasally applied, as control (statistical analysis by Mann-Whitney U Test *p<0.05; **p<0.01; 
***p<0.001). 
 
In order to investigate whether β5i/LMP7 is required for survival of a pneumococcal pneumonia, 
β5i/LMP7-/- and WT mice were monitored for their ability to resist infection (Figure 3.1B). Clinical 
signs were noted in both mouse strains, 60h after intranasal application of 7.5x104 cfu/mouse. These 
signs started mildly and progressed through the clinics of a S. pneumoniae pneumonia. Although, 
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there was no difference in the overall approximate survival rate between WT and β5i/LMP7-/- mice, 
the latter died at earlier time points with an enhanced mortality during the first 108h of infection, 
showing an approximate death rate of about 12 % in WT and about 23.5 % in β5i/LMP7-/- mice. 
The aggravated loss in body weight and drop in body temperature, the premature mortality, and the 
more pronounced expression of SAA suggest an advanced illness in β5i/LMP7-/- mice especially during 
the late phase of pneumonia. 
 
3.2. WT and β5i/LMP7-/- mice react with an overwhelming local immune response  
Physiological signs are associated with immunological observations. Recruitment of leukocytes and 
the local production of inflammatory molecules are central mediators of pathology during disease 
(van der Poll & Opal 2009). In this infection model, influx of immune cells towards lung tissue and 
release of pro-inflammatory cytokines were noted in β5i/LMP7-/- as well as WT mice. Both mouse 
strains established a local overwhelming immune response which increased in strength until death. 
Concerning the recruitment of leukocytes no significant difference was detected between WT and 
β5i/LMP7-/- mice. However, during the late phase of pneumonia, reduced levels of pro-inflammatory 
cytokines were recovered in BAL fluid of β5i/LMP7-/- animals. 
 
3.2.1. Recruitment of inflammatory cells is not disturbed in β5i/LMP7-/- mice 
By illustrating the influence of β5i/LMP7 deficiency on the inflammatory process in lung tissue we 
detected and distinguished levels of infiltrating immune cells at 6h, 24h, and 48h of infection. FACS 
analysis revealed variations in individual cell populations occurring over time.  
 
 
 
 
 
 
 
 
Figure 3.2: Recruitment of leukocytes and lymphocytes towards inflamed lung tissue is not 
influenced by β5i/LMP7 deficiency. Determination of leukocytes and lymphocytes in lung tissue 
analyzed by flow cytometry 48h after application of 5x106 PN36/mouse. As control, 20 l PBS/mouse 
was applied intranasally (each group with n= 4 – 5; statistical analysis by Mann-Whitney Test 
*p<0.05). 
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While there was a strong recruitment of leukocytes towards lung tissue, the amount of lymphocytes 
dramatically decreased. These observations were determined for both, β5i/LMP7-/- and WT mice 
(Figure 3.2). 
Especially during the late phase of pneumonia, leukocytes, mainly neutrophils, were recruited 
towards inflamed lung tissue (Figure 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Recruitment of leukocytes towards inflamed lung tissue is not influenced by β5i/LMP7 
deficiency. Discrimination of several types of leukocytes in lung tissue, analyzed by flow cytometry 
6h, 24h, and 48h after application of 5x106 PN36/mouse. As control, 20 l PBS/mouse was applied 
intranasally (each group with n= 4 – 6; statistical analysis by Mann-Whitney U Test *p<0.05; 
**p<0.01). 
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Its number increased dramatically by approximately 50-fold reaching statistical significance at 24h of 
infection with about 2.4x107 cells/lung. These levels persisted equally elevated at 48h of infection. 
The amount of NK cells remained constant at any time point. The total number of macrophages and 
DCs did not increase until 48h of infection, showing a maximum increase of about 2-fold to about 3-
fold. This was detected in a similar extent for both mouse groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Recruitment of lymphocytes towards inflamed lung tissue is not influenced by 5i/LMP7 
deficiency. Discrimination of several types of lymphocytes in lung tissue, analyzed by flow cytometry 
6h and 24h after application of 5x106 PN36/mouse. As control, 20 l PBS/mouse was applied 
intranasally (each group with n= 2 – 5). 
 
During infection the number of lymphocytes diminished significantly (Figure 3.2). Initially 
approximately 7x106 cells/lung residual lymphocytes were measured in both mouse strains which 
declined to a median of 3.7x106 cells/lung in WT and to a median of 1.8x106 cells/lung in β5i/LMP7-/- 
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mice. A combined reduction in the overall amount of B cells and T cells manifested this decrease, 
already detectable at 24h of infection (Figure 3.4). The numbers of B cells decreased approximately 
5-fold to approximately 8-fold and the quantity of T cells fell about 3-fold to about 4-fold with 
infection. Thereby, all T cell populations were influenced differently. While the quantity of regulatory 
T cells and  T cells was unaffected throughout the whole experiment, the amount of cytotoxic T 
cells and helper T cells was decreased, resembling the range of the decline in the overall amount of T 
cells. This again was detected in a similar extent for both mouse strains.  
Consequently, although, FACS analysis revealed variations in different leukocyte populations in lung 
tissue in response to a pneumococcal pneumonia, no differences in leukocyte recruitment towards 
inflamed lung tissue due to β5i/LMP7 deficiency was measured.  
 
3.2.2. Lung pro-inflammatory cytokines are partially altered due to β5i/LMP7 
deficiency 
Cytokines play a critical role by protecting the host against bacterial infections. They modify various 
immune-modulatory mechanisms that trigger the inflammatory response. Consequently, levels of 
pro-inflammatory cytokines, released to the interstitial alveolar space, were determined in BAL fluids 
of S. pneumoniae infected WT and β5i/LMP7-/- mice (Figure 3.5). Measured cytokines were selected 
based on their known pro-inflammatory impact in host defense (van der Poll & Opal 2009; Koppe et 
al. 2012).  
At 48h of infection, IL-6, TNF, and IL-1were recovered in BAL fluid with a significant increase in 
diseased animals when compared with uninfected control values. Among these cytokines variations 
were detected between β5i/LMP7-/- and WT BAL fluids.  
 
 
 
 
 
 
 
 
 
Figure 3.5: β5i/LMP7-/- mice show reduced levels of certain pro-inflammatory cytokines, measured 
in BAL fluid. Determination of pro-inflammatory cytokines in BAL fluid, obtained 48h after intranasal 
application of 5x106 PN36/mouse, and measured by multiplex analysis. As control, 20 l PBS/mouse 
was applied intranasally (each group with n= 5 – 7; statistical analysis by Mann-Whitney U Test 
*p<0.05). 
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An elevated release of TNF to the interstitial alveolar space was determined in both mouse groups. 
This increase was about 4-fold more pronounced in WT compared to β5i/LMP7-/- mice, though, by 
reason of high variances, this difference did not reach statistical significance. In contrast, IL-
1production revealed significant differences between infected WT and β5i/LMP7-/- animals. In BAL 
fluids of β5i/LMP7-/- mice significantly lower amounts of IL-1 (approximately 12.4 pg/ml) were 
measured compared to that recovered from BAL fluids of infected WT animals (approximately 24.7 
pg/ml). By screening local levels of IL-6 no difference was detected between infected WT and 
β5i/LMP7-/- mice. During infection it increased equally high in both mouse strains with an 
approximated median of 200 pg/ml BAL fluid.  
Taken together, β5i/LMP7-/- animals exhibited reduced pro-inflammatory cytokine levels in the 
alveolar space during the late phase of pneumonia. 
 
3.3. β5i/LMP7-/- mice undergo an advanced case of pneumonia resulting in sepsis 
During the late phase of pneumonia, mice not only suffered from pulmonary inflammation but 
developed signs of an overwhelming systemic immune response which led to sepsis and death. 
Sepsis is characterized by an extensive pro-inflammatory systemic immune reaction which coincides 
with organ damage (Castellheim et al. 2009). This overwhelming immune response often transits into 
a state of immune suppression (Markwart et al. 2014). By applying a lethal dose (LD100) of S. 
pneumoniae to WT and β5i/LMP7-/- mice, prominent systemic immunological effects were 
documented in both mouse strains, though significantly more pronounced in β5i/LMP7-/- animals. 
 
3.3.1. β5i/LMP7-/- mice suffer from a pronounced systemic inflammatory response  
Challenged β5i/LMP7-/- and WT mice not only suffered from pneumonia but developed signs of a 
systemic inflammatory response syndrome (SIRS), indicated by a significant loss in body weight 
(Figure 3.1A) and enhanced expression of SAA (Figure 3.1C). By validating the effect of β5i/LMP7 
deficiency on the severity of the systemic inflammatory response, we quantified and discriminated 
levels of circulating immune cells at 6h, 24h, and 48h of infection. FACS analysis of venous blood 
revealed variations in individual cell populations, especially during the late phase of pneumonia 
(Figure 3.6).  
Although, levels of monocytes remained unaffected throughout the whole experiment the amount of 
granulocytes increased dramatically. Already at 24h of infection, a significant recruitment of 
granulocytes was detected, illustrated by an approximate 2-fold increase in both mouse groups. At 
48h of infection, their total numbers increased further to an approximate 3.5-fold increase in WT 
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animals. This effect did not occur in β5i/LMP7-/- mice, whose granulocyte recruitment diminished to 
an approximate 1.3-fold difference.  
Elevated levels of granulocytes did not automatically result in enhanced amounts of leukocytes. 
Throughout the whole experiment, levels of leukocytes remained unaffected in WT animals, while 
their numbers significantly declined in β5i/LMP7-/- mice (Figure 3.6). Already at 24h of infection, their 
amount of circulating leukocytes decreased by about 35 % lower the leukocyte amount determined 
in uninfected control littermates. This effect persisted significantly and equally high until 48h of 
infection. At this time point, β5i/LMP7-/- mice exhibited significantly less leukocytes compared to WT 
animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: β5i/LMP7-/- mice suffer from a systemic inflammatory response syndrome. 
Determination of blood leukocytes, analyzed by flow cytometry 6h, 24h, and 48h after application of 
5x106 PN36/mouse. As control, 20 l PBS/mouse was applied intranasally (each group with n= 4 – 10; 
statistical analysis by Mann-Whitney U Test *p<0.05, **p<0.01; ***p<0.001).   
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The prominent leukopenia, measured in β5i/LMP7-/- mice, was established by a significant 
lymphopenia (Figure 3.7A). At 24h of infection a reduced level of circulating lymphocytes, which was 
reduced by half, was detected in WT as well as β5i/LMP7-/- mice. At 48h of infection, with an 
advanced state of disease, the total number of lymphocytes decreased further in β5i/LMP7-/- 
animals, establishing a significant difference of about 2-fold between infected WT and β5i/LMP7-/- 
animals. A correlation analysis between body weight, as indicator of health, and amount of 
lymphocytes proved an association of severity of disease and lymphopenia (Figure 3.7B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: β5i/LMP7-/- mice develop lymphopenia that correlates with the severity of illness. (A) 
Determination of blood lymphocyte levels, analyzed by flow cytometry 24h and 48h after application 
of 5x106 PN36/mouse (each group with n= 4 – 10). (B) Illustration of correlation of lymphopenia and 
severity of infection, indicated by body weight. Amount of lymphocytes were determined by FACS 
analysis 48h after application of 5x106 PN36/mouse (each group with n= 9 – 10). (C) Documentation 
of tissue damage 48h post infection by measuring LDH activity in serum of mice, intranasally infected 
with 5x106 PN36/mouse (each group with n= 6 – 7). As control, 20 l PBS/mouse was applied 
intranasally (statistical analysis by Mann-Whitney U Test *p<0.05; **p<0.01; ***p<0.001). 
 
A pronounced systemic inflammatory response that causes and/or is accompanied by peripheral 
tissue injuries is defined as severe sepsis and leads to death of the organism (Castellheim et al. 2009). 
Therefore, in order to assess any kind of tissue damage, we evaluated serum levels of the enzyme 
lactate dehydrogenase (LDH), as it is generally released as a consequence of cell destruction 
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(Rotenberg et al. 1988). At 48h of infection, both, WT and β5i/LMP7-/- mice, showed elevated LDH 
serum levels which, however, were only significantly enhanced in β5i/LMP7-/- animals (Figure 3.7C). 
Conclusively, the strong recruitment of granulocytes at 24h of infection suggests a prominent 
systemic immune reaction which is later, at 48h of infection, accompanied by immunosuppression 
indicated by depletion of circulating leukocytes (lymphocytes, granulocytes).  
These results in combination with the elevated serum levels of LDH indicate a progressed systemic 
inflammatory response which is more pronounced in β5i/LMP7-/- animals. 
 
3.3.2. Pneumonia is accompanied by increased systemic levels of chemokines equally 
high in WT and β5i/LMP7-/- mice 
Chemokines, which are released by various cell-types, are essential for the generation, mobilization, 
and navigation of leukocytes (Cruvinel et al. 2010). Since β5i/LMP7-/- but not WT mice suffered from 
leukopenia, at 48h of infection (Figure 3.6), we screened systemic levels of chemokines, selected 
based on their impact on granulocyte and macrophage recruitment. At 48h of infection, IL-6, CXCL-1, 
G-CSF, and MIP-1 were detected in plasma of both mouse groups with a significant increase in 
diseased animals compared to uninfected control values (Figure 3.8). No difference was detected 
between infected WT and β5i/LMP7-/- mice. All chemokines were synthesized at equal levels in both 
mouse strains demonstrating no dysregulation due to β5i/LMP7 deficiency. 
 
 
 
 
 
 
 
Figure 3.8: Systemic levels of chemokines increase with infection, but do not differ between WT 
and β5i/LMP7-/- mice. Determination of chemokines in plasma, obtained 48h after intranasal 
application of 5x106 PN36/mouse, and measured by multiplex analysis. As control, 20 l PBS/mouse 
was applied intranasally (each group with n= 5 - 7). 
 
3.4. β5i/LMP7 deficiency aggravates bacteremia during the late phase of pneumonia 
When residual immune cells and waves of neutrophils fail to eradicate bacteria, sepsis is caused by 
high levels of bacteria in blood (Castellheim et al. 2009). Since this infection model leads to death 
rather by reason of sepsis than of the initial pulmonary infection (Ahl et al. 2013), we assessed the 
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extent of bacterial growth in lung and determined the magnitude of bacterial migration to 
bloodstream (Figure 3.9). Within the first 24h of infection proliferation of S. pneumoniae was 
documented in lungs of both mouse strains (Figure 3.9A), reaching extremely high numbers (about > 
5.0x107 cfu/lung). Between 24h and 48h of infection, proliferation continued with β5i/LMP7-/- mice 
showing a higher bacterial load compared to infected WT animals. However, due to high variances, 
this difference did not reach statistical significance (median of 4.3x108 cfu/lung in WT and median of 
8.0x108 cfu/lung in      β5i/LMP7-/- mice). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: β5i/LMP7 deficiency is accompanied by an elevated bacterial load. Determination of 
bacterial load 24h and 48h post infection in (A) lung and (B) blood of mice, intranasally infected with 
5x106 PN36/mouse (each group with n= 9 - 10; statistical analysis by Mann-Whitney U Test *p<0.05, 
**p<0.01). 
 
Moreover, hemocultures already became positive at 24h of infection, and at 48h of infection 
approximately 100 % of all β5i/LMP7-/- and WT animals established bacteremia (Figure 3.9B). At 48h 
of infection, β5i/LMP7-/- mice developed a manifested bacterial load, while WT animals cultivated 
significantly less bacteria. Having counted about 1.4x105 cfu/ml in WT mice and about 5.6x105 cfu/ml 
in β5i/LMP7-/- mice, they exposed approximately 4 times more bacteria in circulation.  
Thus, during the late phase of pneumonia, β5i/LMP7-/- mice had an exacerbated bacterial 
dissemination manifested in a significantly higher bacterial burden in blood compared to WT animals. 
 
3.5. β5i/LMP7 deficiency does not affect the integrity of the lung endo-epithelium 
The main interface between the environment and the mammalian host is lined by continuous layers 
of specialized epithelial cells that serve many physiological functions including preventing the entry 
of microbes. Loss of integrity of these epithelial layers predisposes an individual to invasive infections 
(Bals & Hiemstra 2004). The key role of immunoproteasomes resides in the protection of cells against 
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harmful inflammation-induced formation of protein aggregates. This protective effect is ultimately 
essential for the preservation of cell viability (Seifert et al. 2010). Therefore, we examined lung tissue 
damage histopathologically and measured the integrity of the lung endo-epithelium by evaluating 
oedema formation.  
In order to investigate pneumonia induced tissue damage, lesions were qualitatively and 
quantitatively characterized by histopathological examinations of lung tissue obtained from WT and 
β5i/LMP7-/- mice at 24h / 48h of infection (Figure 3.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Pneumococcal pneumonia induces lung tissue damage, equally severe in β5i/LMP7-/- 
and WT mice. Assessment of lung tissue damage by H&E stain. (A) Lungs were analysed 24h after 
intranasal application of 5x106 PN36/mouse (each group with n= 4) and (B) 48h after intranasal 
application of 1x106 PN36/mouse (each group with n= 8). As control, 20 l PBS/mouse was applied 
intranasally to WT C57BL/6J mice (each group with n= 4). 
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Morphological examinations revealed approximately 23 % / 48 % pathological tissue in WT mice and 
about 25% / 50% pathological tissue in β5i/LMP7-/- mice. Both, WT and β5i/LMP7-/- mice, suffered 
from progressive oedema and hepatisation of tissue. These modifications were associated with an 
intense inflammatory response, with an excessive infiltration of neutrophils and tissue injury. This 
damage was documented in both mouse strains with a pathological score of the 4th grade. There 
was no difference detectable between WT and β5i/LMP7-/- mice in inflammation induced tissue 
damage in lung caused by S. pneumoniae, neither at 24h nor at 48h of infection. 
Leakage of the endo-epithelial barrier leads to vascular permeability that results in pulmonary 
oedema (Mizgerd & Skerrett 2008). Therefore, air space filling with protein-rich plasma exudates was 
measured by quantifying concentrations of total protein and serum albumin in BAL fluids (Figure 
3.11). Both parameters increased significantly in diseased animals compared to uninfected control 
values. However, no difference was documented between WT and β5i/LMP7-/- animals. Protein 
concentrations, which increased to a median of 0.78 mg/ml in WT and to a median of 0.89 mg/ml in 
β5i/LMP7-/- mice, as well as serum albumin levels, which increased to a median of 0.19 in WT and to 
a median of 0.22 in β5i/LMP7-/- animals, demonstrated no enhanced aggravation of endo-epithelium 
destruction by reason of β5i/LMP7 deficiency. 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Pulmonary infection provokes oedema formation in lungs of β5i/LMP7-/- and WT mice. 
(A) Detection of cell damage, assessed by determining protein concentration in BAL fluid, obtained 
48h after intranasal application of 5x106 PN36/mouse, performed by BCA (each group with n= 7 - 8). 
(B) Evaluation of leakage the of endo-epithelial barrier by measuring concentrations of serum 
albumin in BAL fluid, obtained 48h after intranasal application of 5x106 PN36/mouse, performed by 
ELISA (each group with n= 7 - 8). 
 
3.6. β5i/LMP7 deficiency affects bacterial elimination 
Considering that elimination of pathogens is a crucial step in host defense during pneumonia, we 
investigated the anti-bacterial properties of WT and β5i/LMP7-/- leukocytes, by studying their ability 
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to phagocytose and eliminate pneumococci. Additionally, since opsonization of bacteria results in 
facilitated pathogen recognition, enhanced phagocytosis, and elimination, we analysed the 
expression of various opsonizing molecules in lung and liver of WT and β5i/LMP7-/- mice. Although, 
no dysregulation of the anti-bacterial leukocyte function due to β5i/LMP7 deficiency was 
documented ex vivo, the in vivo expression of especially systemically located opsonins was affected 
in β5i/LMP7-/- mice. 
 
3.6.1. The efficacy to kill S. pneumoniae is unaffected in β5i/LMP7-/- leukocytes  
Leukocytes, including macrophages and granulocytes, play a central role in the innate immune 
response against extracellular pathogens. One of the main characteristics of these cells is their ability 
to internalize, kill, and degrade microbes (Underhill & Ozinsky 2002). Since β5i/LMP7-/- mice had a 
higher bacterial load in blood during the late phase of pneumonia (Figure 3.9), we investigated the 
impact of β5i/LMP7 deficiency on leukocyte function and their ability to kill bacteria.  
Granulocytes and macrophages are critical in phagocytosis of S. pneumoniae (van der Poll & Opal 
2009). Consequently, we assessed the effect of β5i/LMP7 deficiency on their ability to internalize 
pneumococci. For this purpose, lung leukocytes were isolated from WT and β5i/LMP7-/- mice and 
incubated with fluorochrome-labeled particles. FACS analysis revealed no difference in the amount 
of WT and β5i/LMP7-/- lung macrophages, granulocytes, and dendritic cells, having incorporated this 
particle (Figure 3.12A).  
 
 
 
 
 
 
 
 
Figure 3.12: Phagocytosis of bacteria by leukocytes is not altered due to β5i/LMP7 deficiency. (A) 
Analysis of phagocytosis of fluorochrome-labeled particles by alveolar leukocytes, determined by 
flow cytometry (each group with n= 3). (B) Measurement of the phagocytosis rate of fluorochrome-
labeled heat inactivated D39cps by BMM at different time points, determined by flow cytometry 
(each group with n= 3). 
 
To confirm this result with pneumococcal protein, bone marrow derived macrophages (BMM) were 
incubated with fluorochrome-labeled heat inactivated D39cps. By assessing the amount of 
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incorporated S. pneumoniae by FACS analysis no difference between β5i/LMP7-/- and WT BMM was 
determined (Figure 3.12B). Deficiency of β5i/LMP7 did not influence phagocytosis of S. pneumoniae. 
After internalization, microbes are degraded in mature phagolysosomes. The maturation status, 
which is reflected by the phagolysosomal pH milieu, is an indicator of successful intracellular killing 
(Nüsse 2011). Therefore, we investigated the impact of β5i/LMP7 deficiency on phagolysosomal 
maturation by incubating BMM with pH-dependent-fluorochrome-labeled particles. Subsequent 
FACS analysis revealed changes in the phagolysosomal pH value, decreasing from neutral 
(approximately pH 6.7) to acid (about pH < 4.0) (Figure 3.13A). Acidification was similar in WT and 
β5i/LMP7-/- BMM, indicating no effect of β5i/LMP7 deficiency on phagolysosomal maturation and 
intracellular killing competence.  
This result was confirmed by directly determining the amount of internalized vivid S. pneumoniae. 
We investigated the success of β5i/LMP7-/- macrophages to intracellularly kill S. pneumoniae by co-
cultivating them with active D39cps. Macrophages effectively eliminated S. pneumoniae in the early 
phase of intracellular killing (Figure 3.13B), however, no difference was detected between WT and 
β5i/LMP7-/- macrophages. Furthermore, it is reported that intracellular bacterial elimination is 
enhanced by apoptosis resulting in an improved late phase of intracellular killing (Ali et al. 2003), 
which is induced by phagocytosis of S. pneumoniae itself. We analyzed the efficiency of β5i/LMP7-/- 
BMM to eliminate internalized bacteria in the late phase of killing by co-cultivating them with active 
D39cps for longer periods (Figure 3.13C). The success to eliminate bacteria after 12h of infection 
was equally high in β5i/LMP7-/- and WT BMM. Consequently, β5i/LMP7 deficiency had no impact on 
intracellular killing efficiency. 
 
 
 
 
 
 
 
 
Figure 3.13: Bacterial elimination by leukocytes is not altered due to β5i/LMP7 deficiency. (A) 
Measurement of the pH value in the surrounding of phagocytosed particles, which reflects the 
efficiency of phagolysosomal maturation. This was investigated by flow cytometry (each group with 
n= 3). (B) The intracellular early phase of killing and (C) late phase of killing of D39cps by BMM was 
assessed after indicated time points. Therefore BMM were co-cultivated with D39cps MOI 10, cells 
lysed, and plated on blood agar plates. Finally, cfu/ml was determined (each group with n= 3). 
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Extracellular killing is facilitated by reactive nitrogen species, mainly nitric oxide (NO), which is for 
example produced by macrophages expressing iNOS (Burgner et al. 1999; Cole et al. 2014). Mice 
deficient for iNOS are highly susceptible to systemic infections and suffer from increased 
bacteraemia (Kerr et al. 2004; MacMicking et al. 1995). In order to investigate the competence of WT 
and    β5i/LMP7-/- BMM to produce NO, we stimulated BMM with either LPS or heat inactivated 
D39cps, and determined the production of reactive nitrogen species indirectly by measuring NO2
- 
levels in the supernatant using Griess reagent.  
 
 
 
 
 
 
 
 
 
Figure 3.14: 5i/LMP7-/- BMM produce NO less efficiently. Analysis of NO secretion by WT and 
β5i/LMP7-/- BMM, stimulated either with LPS (1 g/ml) or heat inactivated D39cps lysate (1/100) for 
up to 48h. NO concentrations in the supernatant were photometrically determined by Griess-
Reagent (each group with n= 7; statistical analysis by student´s t-test. * p<0.05) 
 
At 36h and 48h of stimulation, elevated NO2
- levels were detected in both mouse groups. However, 
β5i/LMP7-/- BMM accumulated less NO2
- compared to WT BMM, upon stimulation with LPS or 
pneumococcal protein (Figure 3.14). This result is depicting that β5i/LMP7 deficiency influences NO 
production.  
Unfortunately, it was not possible to demonstrate a link between affected NO release and bacterial 
counts in tissue or blood, since no NO2
- level above the background value was detected in BAL fluid of 
WT or β5i/LMP7-/- mice. This suggests a limited role for reactive nitrogen species on bacterial 
clearance and pneumonia, at least in this infection model. 
 
3.6.2. β5i/LMP7 deficiency diminishes expression of opsonizing molecules 
The on-site as well as systemic expression of various types of opsonizing molecules is an important 
early defense mechanism and its impairment increases the susceptibility to pneumococcal infection 
(van der Poll & Opal 2009).  
Results 
 
50 
 
As the synthesis of opsonizing molecules in lung directly facilitates termination of the pulmonary 
bacterial growth at the site of infection (Ariki et al. 2012; Shishido et al. 2012), we examined mRNA 
expression of collectins and pentraxins, including surfactant protein A (sftpa), surfactant protein D 
(sftpd), C1q (c1qa), and PTX-3 (ptx3), in lungs of diseased WT and β5i/LMP7-/- mice (Figure 3.15). At 
48h of infection, gene expression analysis revealed a significant increase in the expression of sftpa 
and sftpd, which improved by approximately 1.5-fold and approximately 4.5-fold, respectively. 
However, no difference was detected between infected WT and β5i/LMP7-/- animals. The amount of 
PTX-3 mRNA significantly increased upon infection in both mouse strains, though significantly less 
pronounced in β5i/LMP7-/- mice, which was reduced by about 55 % compared to WT animals (Figure 
3.15). Furthermore, expression of c1qa was only significantly induced in WT animals (about 1.7-fold), 
β5i/LMP7-/- mice hardly exhibited any up-regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: β5i/LMP7-/- mice exhibit a diminished expression of opsonizing molecules in lung 
tissue. (A) Gene expression analysis of lungs, 48h after intranasal application of 5x106 PN36/mouse, 
performed by RT and Real Time PCR. As control, 20 l PBS/mouse was applied intranasally (each 
group with n= 5 – 6; statistical analysis by Mann-Whitney U Test *p<0.05).  
 
PTX-3 is expressed by various different cell-types with macrophages being a major source (He et al. 
2007). In order to confirm the in vivo obtained data with in vitro experiments, we assessed PTX-3 
mRNA expression in WT and β5i/LMP7-/- macrophages, co-cultivated with S. pneumoniae (Figure 
3.16). Thereby it was documented that ptx3 expression was induced upon infection in both mouse 
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groups. However, β5i/LMP7-/- macrophages expressed significantly less PTX-3 mRNA compared to WT 
macrophages.  
 
 
 
 
 
 
 
 
Serum opsonizing molecules facilitate elimination of bacteria in bloodstream (Shishido et al. 2012). 
Because β5i/LMP7-/- mice suffered from a pronounced bacterial growth in blood (Figure 3.9B), we 
investigated mRNA expression of circulating collectins, ficolins, and pentraxins, including mannose 
binding lectin MBL (mbl2), c-reactive protein CRP (crp), C1q (c1qa), and Ficolin A (fcna), in liver of 
infected WT and β5i/LMP7-/- mice. It was demonstrated that, upon infection, expression of all 
analyzed opsonins was diminished in β5i/LMP7-/- compared to WT animals (Figure 3.17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: β5i/LMP7-/- mice exhibit diminished expression of opsonizing molecules in liver. Gene 
expression analysis of liver 48h after intranasal application of 5x106 PN36/mouse, performed by RT 
and Real Time PCR. As control, 20 l PBS/mouse was applied intranasally (each group with n= 5 – 14; 
statistical analysis by Mann-Whitney U Test *p<0.05; **p<0.01).  
Figure 3.16: β5i/LMP7 deficiency affects PTX-3 
expression in macrophages. Gene expression analysis of 
BMM, co-cultivated with D39cps lysate (MOI 10) for 4h, 
performed by RT and Real Time PCR (each group with n= 
4, illustrated experiment is representative for 4 individual 
replicates; showing mean+- SD; statistical analysis by 
student’s t-test **p<0.01). 
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At 48h of infection, gene expression analysis revealed a significant decline in MBL mRNA levels in 
both mouse groups, though significantly more prominent in β5i/LMP7-/- mice (about 89 %), reaching 
a difference of about 3.4-fold compared to WT animals (about 62 %). Fcna expression also was down 
regulated upon infection, but only significantly in β5i/LMP7-/- animals. While WT mice showed 
approximately 32.8 % less Ficolin A expression, β5i/LMP7-/- mice expressed approximately 66.9 % less 
Ficolin A. In contrast, expression of C1q mRNA was significantly upregulated in WT animals compared 
to uninfected control mice, though it hardly increased in β5i/LMP7-/- mice. At 48h of infection, 
expression of crp was significantly increased in both mouse strains, though less pronounced in 
β5i/LMP7-/- animals. In β5i/LMP7-/- mice it improved by approximately 1.8-fold, in WT mice by about 
5.0-fold. 
The diminished expression of various different opsonizing molecules in liver, lung, and macrophages 
of β5i/LMP7-/- mice upon S. pneumoniae infection or co-cultivation suggest a functional important 
role of immunoproteasomes in the regulation of genes involved in the anti-bacterial innate immune 
response against S. pneumoniae. 
 
3.6.3. Affected opsonin expression is not the consequence of impaired macrophage 
maturation or cytotoxicity 
Macrophages initiate and coordinate the innate immune response by secreting various pro- and anti-
inflammatory immune-modulating molecules, including pentraxins, NO, but also cytokines, and 
chemokines (Marriott & Dockrell 2007).  
Since only fully activated macrophages secrete immune modulators, we analyzed the maturation 
efficiency of stimulated β5i/LMP7-/- BMM by determining their CD86 surface expression, a co-
stimulatory molecule and activation marker (Cole et al. 2014). After treatment with several different 
stimuli and their combination, an enhanced CD86 surface expression was documented, though at 
equal levels in WT and β5i/LMP7-/- macrophages (Figure 3.18A). Activation is accompanied by 
cytokine secretion (Cole et al. 2014). We therefore investigated induction of IL-1 gene expression in 
stimulated β5i/LMP7-/- BMM. Upon co-cultivation with S. pneumoniae enhanced IL-1 mRNA levels 
were detected but without a significant difference between WT and β5i/LMP7-/- macrophages (Figure 
3.18B).  
These results suggest that β5i/LMP7 deficiency did not influence production of immune-modulating 
molecules by affecting macrophage activation. 
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Figure 3.18: Macrophage activation is not affected by β5i/LMP7 deficiency. (A) WT and β5i/LMP7-/- 
BMM were stimulated either with LPS (1 g/ml), heat inactivated D39cps lysate (1/100) and/or IFN 
100 U/ml for up to 24h, in order to analysis the surface expression of the activation marker CD86 
(illustrated experiment is representative for 3 individual replicates). (B) Gene expression analysis of 
BMM, stimulated for 4h with heat inactivated D39cps lysate (1/100), performed by RT and Real 
Time PCR (each group with n= 4, illustrated experiment is representative for 4 individual replicates; 
showing mean+- SD; statistical analysis by student’s t-test). 
 
Immunoproteasomes are critical for preservation of cell viability by preventing inflammation-induced 
formation of harmful protein aggregates (Seifert et al. 2010). To confirm that the reduction in 
expression of opsonins or decline in secretion of NO is not a consequence of cell death, we 
performed cytotoxicity assays on S. pneumoniae co-cultivated WT and β5i/LMP7-/- macrophages, and 
assessed the grade of liver damage by examining clinical parameters in serum of infected WT and 
β5i/LMP7-/- mice.  
Caspase 3/7 activity, used as indicator for apoptosis, increased by maximal 5-fold in S. pneumoniae 
co-cultivated macrophages. This induction was about 2.5-fold below the caspase activity of MG132 
treated cells, which were used as positive control (Figure 3.19A). LDH activity in the supernatant of 
stimulated WT and β5i/LMP7-/- macrophages, which was used as indicator for necrosis, was only 
determined in positive control cells, treated with MG132 (Figure 3.19A). No necrotic effect could be 
detected in S. pneumoniae co-cultivated macrophages. Generally, no difference was documented 
between stimulated WT and β5i/LMP7-/- BMM.  
Additionally, serum levels of alanine-aminotransferase (ALAT), used as indicator for liver damage, 
was not elevated at 48h of infection, neither in WT nor in β5i/LMP7-/- animals (Figure 3.19B). 
Deficiency in β5i/LMP7 did not provoke excessive inflammation-induced damage of hepatocytes.  
Overall, β5i/LMP7 deficiency did not exacerbate inflammation-induced apoptosis or cytotoxicity in 
macrophages or liver. The diminished expression of opsonizing molecules is not the consequence of 
cytotoxic effects, but presumably the result of gene dysregulation. 
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Figure 3.19: β5i/LMP7 deficiency has no apoptotic or cytotoxic effect upon infection. (A) Analysis of 
the activity of caspase 3/7 in cell lysate and of LDH in supernatant of stimulated BMM. They were co-
cultivated with D39cps (MOI 10) for 4h, or treated with 10 M MG132 for 24h, used as positive 
control (each group with n= 4). (B) Documentation of liver damage, 48h post infection, by measuring 
ALAT activity in serum of mice intranasally infected with 5x106 PN36/mouse. As control, 20 l 
PBS/mouse was applied intranasally (each group with n= 5 – 6).  
 
3.7. β5i/LMP7 deficiency influences intracellular signaling in consequence of 
changes in proteasome composition in macrophages and liver 
Assuming that diminished expression of opsonizing molecules in β5i/LMP7-/- liver (Figure 3.17), lung 
(Figure 3.15), and macrophages (Figure 3.16) upon S. pneumoniae infection and co-cultivation, 
respectively, might be due to altered proteasome function in consequence of changes in proteasome 
content and composition, we determined proteasome protein expression in different cell-types, 
without and upon S. pneumoniae infection. We also analyzed the impact of β5i/LMP7 deficiency on 
intracellular signaling transduction pathways resulting in gene transcription of inflammatory 
mediators. Certainly, due to the absence of the β5i/LMP7 subunit, the composition of proteasomes 
has been altered. Upon stimulation, these modifications were accompanied by alterations in 
transcription factor activation.  
 
3.7.1. β5i/LMP7 deficiency alters proteasome subunit composition in liver and in 
macrophages independent of infection  
In liver, CRP, MBL, and Ficolin A  are expressed in hepatocytes but C1q is mainly secreted by Kupffer 
cells (macrophages) (Eisen et al. 2006; He et al. 2007; Mold et al. 2002; Lu et al. 2008). It has been 
reported that both cell-types constitutively express immuno-subunits (Vasuri et al. 2010). We 
confirmed this by immuno-blot (Figure 3.20A), showing a positive signal for all three immuno-
subunits in WT liver. Also standard -subunits were expressed, showing a signal for the 1- and 5-
protein. Liver of β5i/LMP7-/- mice had no 5i/LMP7 protein and less intensive signals for 1i/LMP2 
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and 2i/MECL-1. The protein amount of the 1-subunit remained unchanged but the signal for the 
5-subunit was enhanced. The overall amount of proteasome did not change due to β5i/LMP7 
deficiency, indicated by equal levels of 4 protein in WT and β5i/LMP7-/- mice. Upon infection 
subunit composition did not change, neither in WT nor in β5i/LMP7-/- liver, indicated by unaltered 
signals for all analyzed -subunits. 
In lungs, SP-A and SP-D are expressed in alveolar epithelial cells (Bals & Hiemstra 2004), and PTX-3 as 
well as C1q expression is mostly regulated in macrophages (He et al. 2007; Lu et al. 2008). In order to 
assess β5i/LMP7 protein expression in distinct lung cell populations we scrutinized β5i/LMP7 protein 
expression in uninfected WT lung tissues but also upon S. pneumoniae infection using immune 
precipitation (Figure 3.20B). Infiltrating lymphocytes and granulocytes, but also residual 
macrophages exposed a positive signal for the β5i/LMP7 protein with and without infection. 
However, no β5i/LMP7 protein was detected in alveolar epithelial or endothelial cells. Expression of 
the β5i/LMP7 protein in these cells was not induced upon S. pneumoniae infection. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.20: Immuno- and standard subunits are constitutively expressed in leukocytes and liver 
cells. (A) Analysis of expression of proteasome catalytic -subunits on protein level in liver lysate, 
48h after intranasal application of 5x106 PN36/mouse, performed by immuno-blot. (B) Visualization 
of β5i/LMP7 expression in inflamed lungs by immune precipitation. Lungs were analyzed 24h after 
intranasal application of 5x106 PN36/mouse. As control, 20 l PBS/mouse was intranasally applied to 
WT C57BL/6J mice (each group with n= 4, showing representative pictures). (C) Analysis of expression 
of proteasome catalytic -subunits on protein level in BMM lysate performed by immuno-blot (each 
group with n= 3). 
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Likewise alveolar macrophages, BMM constitutively express immuno-subunits (Figure 3.20C). 
Macrophages deficient in β5i/LMP7 did not only lack β5i/LMP7 protein but also showed reduced 
amounts of β1i/LMP2 and β2i/MECL-1. The overall amount of proteasomes did not change, indicated 
by equal amounts of 4 protein in WT and β5i/LMP7-/- macrophages. 
These results suggest that in cells constitutively expressing β5i/LMP7 such as macrophages or 
hepatocytes the absence of β5i/LMP7 is associated with diminished expression of immune 
modulators. 
 
Hypothesizing that the absence of β5i/LMP7 alters proteasome function in consequence of changes 
in proteasome composition, we determined the impact of β5i/LMP7 deficiency on proteasome 
composition by 2D gel electrophoresis of purified β5i/LMP7-/- and WT BMM 20S proteasomes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: WT macrophages assemble immuno and standard -subunits and β5i/LMP7-/- 
macrophages standard -subunits. (A) 2D gel electrophoresis of purified 20S proteasomes, isolated 
from WT and β5i/LMP7-/- BMM. Proteasome subunits were visualized by coomassie staining. (B) 
Determination of -subunits, incorporated in BMM 20S, detected by immuno-blot. 
 
WT macrophages assembled immuno- and standard subunits, whereas β5i/LMP7-/- macrophages 
mainly exhibited standard proteasomes (Figure 3.21A). Densitometrical analysis of 5 and 5i/LMP7 
spots proved that macrophages expressed approximately 40 % 5 and approximately 60 % 5i/LMP7. 
In β5i/LMP7-/- 20S proteasomes, the disappearance of the β5i/LMP7 protein was accompanied by an 
increased incorporation of the standard 5-subunit. The absence of β5i/LMP7 had a negative 
influence on the protein amount of β1i/LMP2 and β2i/MECL-1 that was markedly less incorporated in 
20S proteasomes (Figure 3.20B).  
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These results indicate that 5i/LMP7 deficiency alters proteasome subunit composition independent 
of stimulation. 
 
3.7.2. Deficiency in 5i/LMP7 is accompanied by a modified intracellular signaling in 
stimulated macrophages 
Recognition of pathogens by TLRs initiates induction of several intracellular signaling cascades 
resulting in transcription factor activation including NFB and AP-1. Activation of these nuclear 
factors is crucial for the transcriptional regulation of various different inflammatory mediators 
(Newton & Dixit 2012). Assuming that altered proteasome composition or proteasome inhibition 
might have an influence on proteasome function for modulating intracellular signaling cascades and 
thereby influences gene transcription, we assessed the pathogen induced activation of AP-1 and 
NFB in β5i/LMP7-/- or epoxomicin pretreated macrophages. 
Pathogen recognition results in NFB activation via IB degradation by the proteasome (Cuschieri 
et al. 2004). In order to investigate the impact of β5i/LMP7 deficiency on proteasomal IB 
degradation following LPS stimulation or D39cps co-cultivation, we performed immuno-blot 
analyses on in vitro stimulated BMM (Figure 3.22A/B). At 30min of stimulation and co-cultivation, 
respectively, the IB protein disappeared in both, WT and β5i/LMP7-/- macrophages. There was no 
impaired IB degradation, and presumably no weakened NFB activation, following pathogen 
stimulation due to β5i/LMP7 deficiency. 
Unlike NFB, AP-1 activation and nuclear translocation is not the consequence of the degradation of 
an inhibitor protein but the result of phosphorylation of its components, mediated by MAPKs 
(Newton & Dixit 2012; Cuschieri et al. 2004). In order to study the influence of β5i/LMP7 deficiency 
on AP-1 activation we detected its components, cJun, cFos, and ATF-2, together with their 
phosphorylated forms in LPS stimulated or D39cps co-cultivated BMM by immuno-blot (Figure 
3.22A/B). LPS stimulation or S. pneumoniae co-cultivation resulted in AP-1 activation indicated by a 
robust phosphorylation of cJun, cFos, and ATF-2, which was more pronounced in β5i/LMP7-/- 
compared to WT macrophages. Phosphorylation was already detected after 30min of stimulation for 
cJun and ATF-2, and after 2h of stimulation for cFos. Protein expression of all three AP-1 components 
was only minimally up-regulated in WT and β5i/LMP7-/- macrophages upon pathogen recognition. 
However, β5i/LMP7-/- macrophages expressed higher levels of cJun, cFos, and ATF-2, which exhibited 
enhanced phosphorylated statuses, even in the absence of stimulation.  
Enhanced AP-1 activation following stimulation due to impaired proteasome function was confirmed 
in macrophages pretreated with the proteasome inhibitor epoxomicin (Figure 3.22C). Depending on 
its concentration, this inhibitor covalently binds and thereby inhibits certain proteolytically active -
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subunits of the proteasome. In this experiment, epoxomicin mainly inhibited the chymotrypsin-like 
activity of the protreasome by binding at 5, 5i/LMP7, and 1i/LMP2, but not at 1 and 2i/MECL-
1, indicated by a molecular shift in immuno-blot (Figure 3.22D).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22: 5i/LMP7 deficiency as well as proteasome inhibition enhances AP-1 activation in 
stimulated macrophages. (A-B) Immuno-blot on phosphorylated and non-phosphorylated members 
of AP-1 and the NFB activating pathway in WT and 5i/LMP7-/- BMM, stimulated in vitro for 0h, 
30min, and 240min with (A) LPS (1 g/ml) or (B) D39cps (MOI 10) (each group with n= 3). (C) 
Immuno-blot on phosphorylated and non-phosphorylated cJun in RAW264.7 cells, pretreated with 
DMSO or epoxomicin (250 nM) for 2h, and subsequently stimulated with LPS (1 g/ml) or D39cps 
(MOI 10) for 0h, 2h, 4h, and 6h. (D) Immuno-blot on catalytic -subunits of the proteasome in 
RAW264.7 cells incubated for 2h with DMSO or epoxomicin (250 nM). Molecular shift indicates 
inhibitor binding.  
 
Macrophages, pretreated with epoxomicin, exhibited an enhanced protein level of cJun exposing a 
stronger phosphorylation signal without further stimulation. Following LPS stimulation or D39cps 
co-cultivation cJun protein expression and phosphorylation was induced, though, more pronounced 
in epoxomicin pretreated cells.  
These results suggest that changes in proteasome composition or inhibition have a selective effect on 
transcription factor activation, which presumably influence gene transcription upon S. pneumoniae 
co-cultivation.
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4. Discussion 
Since there is a strong need to improve the understanding of host defense mechanisms influencing 
progression of pneumococcal infection we investigated the involvement of the immuno-subunit 
β5i/LMP7 in antibacterial defense mechanisms of the innate immune system, by using a murine 
infection model. This S. pneumoniae infection model is a model of untreated fatal pneumonia. 
Macrophages, neutrophils, and lymphocytes failed to clear pneumococci which proliferated and 
induced bacteremia in addition to the initial pulmonary infection. All mice, developed a sequential 
pathogenesis with a lethal outcome. Thereby, β5i/LMP7-/- mice developed critical illness resulting in 
an aggravated systemic inflammatory response with enhanced bacteremia likely due to a diminished 
expression of opsonizing molecules. 
 
4.1. β5i/LMP7-/- mice suffered from critical illness 
The body weight is a common noninvasive diagnostic parameter, employed in animal infection 
studies, predicting infection, inflammation, and physiological sequelae (Olfert & Godson 2000). 
Decreased body weight indicates the severity of disease. S. pneumoniae infected animals developed 
a gradual loss in body weight which was significantly stronger in β5i/LMP7-/- compared to WT animals 
(see figure 3.1A). The decrease in body weight is likely due to changes in behavior and metabolism, 
because cytokines, released upon infection, affect production of appetence and anorexia (Mizgerd & 
Skerrett 2008). The loss in body weight was accompanied by a significant drop in body temperature 
in β5i/LMP7-/- mice but not in WT animals (see figure 3.1A). It is known that animals in a septic state 
lose their ability to maintain their body temperature. A decrease beyond a certain point has been 
correlated with a lethal outcome in several infectious diseases (Olfert & Godson 2000). Kerr et al. 
suggested that a drop in body temperature in mice infected with pneumococci accurately mirrors the 
health of animals as it preceded with a fundamental pulmonary inflammation. The decrease might be 
induced by a strong cytokine production, which stimulates prostaglandin release and temperature 
change (Kerr et al. 2002). A severe state of illness during the late phase of pneumonia was confirmed 
by a prominent acute phase response which was significantly more pronounced in β5i/LMP7-/- 
animals (see figure 3.1C). Acute phase proteins are synthesized in hepatocytes after cytokine 
stimulation in response to infection, inflammation, and trauma (Yamada 1999). The major acute 
phase protein, synthesized in mice, is serum amyloid A (Olfert & Godson 2000). High levels of SAA 
accurately correlate with the presence and severity of infection, and thus, are commonly used as 
diagnostic marker for the extent and outcome of infection (Yamada 1999). These clinical signs 
suggest a higher morbidity and a more severe course of pneumococcal disease with critical illness in 
β5i/LMP7-/- mice, especially during the late phase of pneumonia.  
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Critical illness ensues premature mortality. Although, there was no difference in the overall 
approximate survival rate between infected WT and β5i/LMP7-/- mice, the latter reached the 
predetermined human endpoint at earlier time points (see figure 3.1B), indicating a more progressive 
case of pneumococcal pneumonia with an advanced chronology of microbiological and 
immunological procedures. Survival studies predict resistance to infection and validate the clinical 
relevance of medical treatments or genetic deficiencies. 
By determining immunological events at certain time points of infection, it was possible to classify 
the status of disease in WT as well as β5i/LMP7-/- mice. Both, WT as well as β5i/LMP7-/- mice 
underwent characteristic pathogenesis steps, described by Bergeron at al., who characterized the 
chronology of events associated with fatal pneumococcal pneumonia by determining and correlating 
levels of cytokines as well as leukocyte in BAL fluid and blood with the time course and outcome of 
pneumonia. Thereby they identified the major pathogenesis steps from the initial infection to death. 
The first steps (0h - 24h) involved a local pulmonary infection, with partial but ineffective bacterial 
clearance by alveolar macrophages, bacterial growth, and recruitment of neutrophils in blood and 
lung. The next step (24h - 48h) was described by a transition from pulmonary to systemic infection, 
with high amounts of leukocytes in lung and blood and bacterial dissemination (Bergeron et al. 
1998). During the first steps of infection, WT as well as β5i/LMP7-/- mice developed similar 
immunological statuses. Amounts of lung and circulating granulocytes increased dramatically while 
levels of lymphocytes, both B and T cells, declined (see figure 3.3, 3.4, 3.6). Bergeron et al described 
the last pathogenesis step (> 48h) with a systemic inflammatory response syndrome that led to 
severe tissue injuries and death. The overall inflammation during the late phase of pneumonia was 
characterized by immune suppression, defined by decreased levels of circulating leukocytes including 
neutrophils and lymphocytes (Bergeron et al. 1998). During the late phase of pneumonia, WT mice 
exhibited a highly activated immune system, while, despite progression of disease, β5i/LMP7-/- mice 
transited to a state of immune suppression. At 48h of infection, the amount of circulating 
granulocytes peaked in WT mice and diminished in β5i/LMP7-/- animals (see figure 3.6). This was not 
a consequence of reduced neutrophil enrolment due to missing chemokines, because CXCL-1 and G-
CSF plasma levels, promoting development and recruitment of granulocytes, were at equal levels in 
both mouse strains (see figure 3.8).  
Although, amounts of leukocytes remained unaffected in WT animals they significantly declined in 
β5i/LMP7-/- mice resulting in a prominent leukopenia (see figure 3.6). This was established by a 
significant lymphopenia and correlated with the magnitude of illness (see figure 3.7). Immune 
suppression, signified by lymphopenia, is a common event of a systemic infection leading to critical 
illness and death (Hotchkiss et al. 2009; Drewry et al. 2014). S. pneumoniae is an important cause of 
sepsis in humans, generally occurring as a form of an advanced stage of pneumonia (Garcia-Vidal et 
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al. 2010; Chiou & Yu 2006). Sepsis is defined as a systemic inflammatory response syndrome (SIRS) 
that occurs during severe microbial infection and is diagnosed by clinical parameters such as blood 
leukocyte counts, body temperature, and release of acute phase proteins (Lever & Mackenzie 2007). 
It is characterized by a massive activation of the immune system with leukocyte recruitment and 
activation but also with an excessive production of inflammatory mediators, such as cytokines and 
ROS. In the acute phase of fatal sepsis, the overwhelming immune reaction transits into a state of 
immune depression, provoked by an anti-inflammatory response and manifested as lymphopenia, 
affecting both B cells and T cells (Castellheim et al. 2009; Drewry et al. 2014). There are multiple 
cellular mechanisms which might trigger immune suppression. One explanation for sepsis-associated 
immune suppression appears to be apoptosis of cells of the innate and adaptive immune system due 
to TNF release or due to direct effects of bacterial toxins or bacteria themselves (Hotchkiss et al. 
1999). Depletion of white pulpa and bone marrow also could cause an immune compromised state, 
resulting in leukopenia. 
Although there was no difference in the cellular composition in lung tissue between both mice 
strains, cytokine levels, recovered from BAL fluid, varied. Reduced TNF and significantly less IL-1 
levels were recovered in BAL fluid of β5i/LMP7-/- mice compared to WT animals (see figure 3.5). 
Alveolar levels of IL-6 were equally elevated in infected WT and β5i/LMP7-/- mice. Bergeron et al. 
documented a transient appearance of TNF and IL-1 in BAL fluid of lethally infected animals which 
peaked within the first 12h of infection and dropped to basal level during the late phase of 
pneumonia, whereas IL-6 levels in BAL fluid peaked early after infection and persisted increased. 
While IL-6 probably reflects the severity of stress rather than severity of infection (Bergeron et al. 
1998), the transient appearance and especially the drop in TNF and IL-1 in BAL fluid of β5i/LMP7-/- 
animals indicates a progressed step in the pathogenesis of infection and thus a state towards a more 
profound illness.  
Critical illness, coinciding with organ dysfunction and peripheral tissue damage, is defined as severe 
sepsis (Castellheim et al. 2009). Elevated LDH serum levels, which indicate general cell destruction, is 
a clinical diagnostic marker, predicting tissue damage (Rotenberg et al. 1988). Only β5i/LMP7-/- 
animals exhibited significantly enhanced LDH serum levels (see figure 3.7C). This supports the 
phenotype of β5i/LMP7-/- mice of a more pronounced critical illness during the late phase of 
pneumonia.  
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4.2. Neither leukocyte function nor endo-epithelial leakage but diminished opsonin 
expression coincided with enhanced bacteremia in β5i/LMP7-/- mice 
Leukopenia often coincides with bacteremia, which is defined as case of systemic infection with 
bacteria present in blood (Castellheim et al. 2009). When residual immune cells and infiltrating 
granulocytes fail to eliminate S. pneumoniae, bacteria proliferate, disseminate, and provoke 
peripheral tissue damage leading to death of the organism. During the late phase of pneumonia, 
β5i/LMP7-/- mice developed a significantly stronger pneumococcal dissemination compared to WT 
animals, manifested in an enhanced bacterial burden in blood (see figure 3.9B).  
Pneumococcal dissemination is facilitated by serious damage of the alveolar endo-epithelium, 
provoked by for example TNFrelease, granulocyte activity, and pneumococcal virulence factors 
such as LTA and Ply (Bergeron et al. 1998; Cundell et al. 1995). Leakage of the endo-epithelial barrier 
leads to vascular permeability that results in pulmonary oedema (Mizgerd & Skerrett 2008). 
Exudates, consisting of inner cell contents and serum proteins, serve as a source of nutrients, support 
bacterial growth, and predispose individuals to systemic infection (Bals & Hiemstra 2004). Although, 
previous data discussed the importance of immunoproteasome formation during inflammation for 
preservation of cell viability by protecting cells against harmful formation of protein aggregates 
(Seifert et al. 2010; Opitz et al. 2011) we could not prove aggravated endo-epithelium destruction by 
reason of β5i/LMP7 deficiency (see figure 3.11, 3.10).  
Leukocytes, including macrophages and granulocytes, are central for eradication of S. pneumoniae. 
One of the main characteristics of these cells is their ability to internalize and kill bacteria (Underhill 
& Ozinsky 2002). However, the intracellular killing properties were not affected in β5i/LMP7-/- 
leukocytes. Deficiency in β5i/LMP7 did not influence the ability of lung macrophages, granulocytes, 
and dendritic cells to phagocytose bacteria (see figure 3.12). It neither affected phagolysosomal 
maturation, nor the intracellular early and late phase killing competence of BMM (see figure 3.13), 
nor influenced their activation efficiency (see figure 3.18). Interestingly, S. pneumoniae stimulated 
β5i/LMP7-/- macrophages released reduced levels of nitric oxide (NO) (see figure 3.14), which is 
shown to control pneumococcal viability (Kerr et al. 2004). These results are in accordance with 
recently published data by Reis et al., who reported diminished NO production in β5i/LMP7-/- 
macrophages stimulated with LPS (Reis et al. 2011). Although Bergeron et al. documented a 
sustained release of NO in BAL fluid during the late phase of pneumonia (Bergeron et al. 1998), we 
were not able to detect NO release in BAL fluid of either WT or β5i/LMP7-/- mice, and thus were not 
able to demonstrate a link between NO release and bacterial burden. These results suggest an 
impact of β5i/LMP7 deficiency on the synthesis of NO, which may only have a limited impact on the 
magnitude of bacterial load in tissue or blood, at least in this infection model.  
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Despite an efficient leukocyte effector function, bacterial clearance can be affected by impaired 
bacterial opsonophagocytosis. Opsonization is a crucial step during pathogen elimination that 
enables bacterial recognition, enhances bacterial internalization, and facilitates bacterial degradation 
(Ariki et al. 2012; Shishido et al. 2012).  
The on-site expression of opsonizing molecules directly facilitates termination of pulmonary bacterial 
growth in lung tissue. SP-A, SP-D, and C1q as well as PTX-3, whose synthesis increased during S. 
pneumoniae infection, are locally expressed by various different alveolar cell types (Bottazzi et al. 
2010; Ariki et al. 2012). Although PTX-3 mRNA expression increased in lungs of both mouse strains, 
β5i/LMP7-/- mice exhibited significantly less PTX-3 mRNA levels (see figure 3.15). The influence of 
β5i/LMP7 deficiency on PTX-3 expression was reproduced ex vivo with S. pneumoniae co-cultivated 
β5i/LMP7-/- macrophages that exhibited significantly less PTX-3 mRNA compared to WT macrophages 
upon S. pneumoniae co-cultivation (see figure 3.16). Its protective role during lung infections was 
observed by Moalli et al. who showed that PTX-3-/- mice were highly susceptible towards infection 
with Pseudomonas aeruginosa. They also reported that recombinant PTX-3 facilitated pathogen 
clearance by promoting an appropriate immune response in the lungs of PTX3-/- mice (Moalli et al. 
2011). PTX-3 is produced in lung mainly in macrophages and binds to microbial surface structures 
and complement components including C1q, MBL, and Ficolin and thereby amplifies the effector 
functions of the complement system (Inforzato et al. 2013; Doni et al. 2012). The similar expression 
of surfactant proteins in WT and β5i/LMP7-/- lungs, which are produced by type II alveolar epithelial 
cells upon cytokine stimulation (Crouch & Wright 2001), may explain the remote effect of β5i/LMP7 
deficiency on bacterial replication in lungs (see figure 3.9A). Although, SP-A and SP-D expression 
increased significantly at the late phase of infection, no difference was detected between WT and 
β5i/LMP7-/- animals (see figure 3.15). In vivo studies revealed that SP-A and SP-D are involved in 
bacterial clearance by directly interacting with S. pneumoniae and stimulating pneumococcal uptake 
by phagocytes (Crouch & Wright 2001; Hartshorn et al. 1998).  
Systemic opsonizing molecules such as the pentraxin CRP and the complement components C1q, 
MBL, and Ficolin A promote elimination of invading S. pneumoniae (Bottazzi et al. 2010; Shishido et 
al. 2012). In animal models, human CRP protects against a lethal infection with S. pneumoniae, and in 
humans, it contributes to host defense during a bacteremic pneumonia (Suresh et al. 2007). In this 
mouse model, CRP expression was significantly increased in both, WT and β5i/LMP7-/- animals, 
though less pronounced in β5i/LMP7-/- mice. CRP binds to phosphorylcholine in pneumococcal cell-
wall, C1q, as well as Ficolin, and thereby facilitates complement activation via the classical and lectin 
pathway (Suresh et al. 2006). It is produced in liver in response to cytokine stimulation, mostly 
contributed by IL-6, and to a lesser degree by IL-1 (Cha-Molstad et al. 2000). The reduced CRP 
expression is not in consequence of low cytokine stimulation because IL-6 levels were at equal levels 
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in WT and β5i/LMP7-/- mice (see figure 3.8). In addition to CRP, liver expression of other opsonizing 
molecules, initiating complement activation, was diminished due to β5i/LMP7 deficiency. Likewise 
lung expression, liver expression of C1q was only significantly induced in WT but not in β5i/LMP7-/- 
animals, MBL mRNA levels significantly declined in both mouse groups, though significantly more 
prominent in β5i/LMP7-/- mice, and Ficolin A expression was only significantly down regulated in 
β5i/LMP7-/- animals. C1q, MBL, and Ficolin A either directly opsonize bacteria or promote 
complement mediated opsonization (Bottazzi et al. 2010). The complement-mediated 
opsonophagoytosis is critical in competing with S. pneumoniae. C1q activates the classical 
complement pathway upon interaction with immunoglobulin or pentraxin containing immune 
complexes (Bottazzi et al. 2010). The lectin pathway is initiated by the binding of MBL or Ficolin at 
carbohydrate structures on the surface of pathogens or bound pentraxins (Bottazzi et al. 2010). 
Complement activation leads to C3b deposition on the bacterial surface which is further processed to 
C3b, also acting as opsonin for phagocytosis (Sarma & Ward 2011). The C1q mediated complement 
activation pathway is supposed to be the dominant complement pathway which is required for an 
effective innate immune reaction against S. pneumoniae.  C1q deficiency results in an impaired C3b 
deposition and increased systemic replication of pneumococci, leading to an enhanced susceptibility 
to S. pneumoniae infection (Brown et al. 2002). However, recently published data also demonstrate 
the importance of the lectin complement pathway for resistance against S. pneumoniae. Ali et al. 
reported that the complete absence of the lectin cascade, achieved by MASP-2 deficiency, led to a 
total loss of C3b deposition, Ficolin A deficiency resulted in impaired C3b deposition, and MBL 
deficiency had no influence on C3b deposition. These results promoted Ficolin A as the key 
recognition component of the lectin activation pathway, which is essential for an effective host 
defense against pneumococcal infection (Ali et al. 2012). Nevertheless, it is also reported that 
patients, homozygotes for an MBL codon variant exhibited reduced MBL serum levels and were 
highly susceptible to invasive pneumococcal infections (Roy et al. 2002).  
Deficiency in β5i/LMP7 did not exacerbate inflammation-induced apoptosis or cytotoxicity in liver or 
macrophages (see figure 3.19). The diminished expression of opsonizing molecules is not the 
consequence of cytotoxic effects, but may be the result of affected gene regulation provoked by 
altered proteasome function in consequence of changes in proteasome composition. 
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4.3. Altered proteasome composition is accompanied by affected gene transcription 
of immune modulating molecules in liver and macrophages 
Proteasome composition differs among cell types and tissues, adapted to their individual functional 
needs. For example, spleen mainly contains immunoproteasomes, heart expresses standard 
proteasomes, and liver assembles intermediate proteasomes (Guillaume et al. 2010; Ebstein et al. 
2012; Gohlke et al. 2014). The absence of the β5i/LMP7 subunit has a substantial impact on the 
assembly and composition of proteasomes in cells constitutively expressing or upregulating immuno-
subunits. Changes in the cellular pool of proteasomes lead to altered proteasome activities and/or 
cleavage preferences that effect cell and tissue function during infection and inflammation (Joeris et 
al. 2012). The impact of proteasome composition and function on pathogen elimination and 
inflammation varies between pathological challenges but also inflamed tissue.  
For example, by analyzing the importance of immunoproteasome activity for an efficient antiviral 
immune response in mice, Basler et al. reported that LPS or anti-CD3/CD28 stimulated splenocytes, 
devoid of immunoproteasome activity, secreted reduced levels of IL-6, TNF, and IFN, but equal 
amounts of IL-10 (Basler et al. 2011). Kremer et al. described a less pronounced LCMV-induced 
meningitis in β5i/LMP7-/- mice and suggested that β5i/LMP7-/- microglia cells, which express 
β5i/LMP7, and not astrocytes, which lack β5i/LMP7, prevent immunopathological damage by 
exhibiting a lower pro-inflammatory status (Kremer et al. 2010). Infection with L. monocytogenes 
rapidly enhances β5i/LMP7 expression in liver which is essential to exceed the quantity of 
immunogenic peptides presented on MHC class I molecules. Antigen presentation in infected 
β5i/LMP7-/- hepatocytes was insufficient resulting in an impaired bacterial clearance due to a weak 
CTL response in liver (Strehl et al. 2006). Modulation of the proteasome activity, either by β5i/LMP7-/- 
or proteasome inhibition, attenuated experimental colitis, by limiting the secretion of pro-
inflammatory mediators, such as IL-1, IL-6, TNF, IFN, and IL-17, determined in colon of inflamed 
animals. By using bone marrow chimeras it was confirmed that β5i/LMP7-/- predominantly affected 
the induction of the pro-inflammatory program within leukocytes, constitutively expressing 
β5i/LMP7, but not in intestinal epithelial cells (Schmidt et al. 2010). In the here described S. 
pneumoniae infection model, affected gene transcription of immune modulating molecules coincided 
with an altered proteasome composition and presumably function in macrophages and liver. A 
correlation between cell specific expression of immune modulating molecules and β5i/LMP7 
expression was documented by scrutinizing β5i/LMP7 protein expression in lung and liver tissue. 
Alveolar macrophages as well as infiltrating granulocytes exhibited β5i/LMP7 protein in WT mice with 
and without infection, however, β5i/LMP7 protein was not expressed and neither induced in alveolar 
epithelial cells upon infection (see figure 3.20). This is in accordance with recently reported data by 
Keller et al., who detected only very low amounts of immuno-subunits in alveolar epithelial cells, but 
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highly positive signals for β1i/LMP2 in alveolar macrophages (Keller et al. 2015). Vasuri et al. 
documented the presence of immuno-subunits, in different cell-types of healthy human liver tissue 
including hepatocytes and Kupffer cells (Vasuri et al. 2010). Guillaume et al. characterized 20S 
proteasomes, isolated from human monocytes as well as liver, and found proteasomes comprising 54 
% intermediate proteasomes in both isolates. Furthermore, monocytes assembled 15 % standard and 
31 % immunoproteasomes, and liver consisted of 31 % standard and 15 % immunoproteasomes 
(Guillaume et al. 2010). Moreover, Gohlke et al. documented that rat liver exclusively assembled 
intermediate proteasomes, mainly incorporating both the β1i/LMP2 and β5i/LMP7 immuno-subunit 
(Gohlke et al. 2014). Intermediate proteasomes assemble in the absence of and remain unchanged 
following stimulation or inflammation (Guillaume et al. 2010). The same was documented in liver of 
S. pneumoniae challenged mice. Under healthy conditions liver proteasomes incorporated both, 
standard and immuno-subunits, and were unchanged during pneumococcal pneumonia, in WT but 
also β5i/LMP7-/- animals (see figure 3.20). The appearance of the β5i/LMP7 protein in macrophages 
and hepatocytes and its absence in alveolar epithelial cells suggest a link between β5i/LMP7 
deficiency and reduced expression of PTX3, C1q, MBL, Ficolin A, and unaffected expression of SP-A 
and SP-D (Eisen et al. 2006; He et al. 2007; Mold et al. 2002; Lu et al. 2008). 
By investigating the composition of purified 20S proteasomes, isolated from  β5i/LMP7-/- and WT 
BMM, it became apparent that WT macrophages assembled immuno- and standard -subunits, 
presumably forming immuno- and intermediate proteasomes, while β5i/LMP7-/- macrophages mainly 
incorporated standard -subunits, forming standard proteasomes (see figure 3.21). De et al. 
documented that, in the absence of β5i/LMP7, the constitutive counterpart is incorporated into 20S 
immunoproteasomes (De et al. 2003). In addition, the remaining immuno-subunits, β1i/LMP2 and 
β2i/MECL-1, exhibit an affected incorporation due to their cooperative assembly  (Griffin et al. 1998; 
Groettrup et al. 1997).  
 
4.4. Proteasomes fine-tune pathogen mediated cell signaling and gene transcription 
Different proteasome sub-types exhibit different enzymatic properties, first reported by Dahlmann et 
al., who isolated and characterized a pool of rat muscle 20S proteasomes. They reported that 
different proteasome sub-types differ in their degradation rate and quality of generated products 
(Dahlmann et al. 2000). Since the crystal structure of the active site of immunoproteasomes differ 
from that of standard proteasomes (Huber et al. 2012), the presence or absence of a catalytic 
subunit could structurally change the conformation of the catalytic chamber, altering its specificity 
for substrates. Therefore, it may be conceivable that different proteasome sub-types influence gene 
transcription by differential degrading specific proteins of intracellular signaling cascades or by 
degrading regulatory molecules that either inhibit or activate gene transcription.  
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It has been reported that proteasomes play a regulatory role in inflammatory-mediated intracellular 
signaling pathways resulting in NFB and AP-1 activation and thus modulate gene transcription 
(Gerber et al. 2004; Cuschieri et al. 2004). Considering iNOS expression NFB activation has a master 
regulating role since microbial compounds induce but antioxidants reduce iNOS expression by 
directly targeting NFB nuclear translocation (Pautz et al. 2010). In case of CRP expression NFB 
functions as a synergistic modulator, via enhancing the inducing effect of other nuclear factors such 
as C/EBP and STAT3, (Cha-Molstad et al. 2000). NFB activation is mediated by the proteasome 
through degradation of the inhibitor protein IB and the NFB precursor protein p105 (Visekruna et 
al. 2006). The role of especially immunoproteasomes, in case of NFB activation, has been 
controversially discussed. Following LPS or S. pneumoniae stimulation IB degradation was not 
impaired in β5i/LMP7-/- macrophages (see figure 3.22A/B). However, to clarify the impact of 
β5i/LMP7 deficiency on NFB activation upon S. pneumoniae co-cultivation more sensitive readout 
systems, such as ELISA against p65 on nuclear extracts, are necessary. The multiplicity of studies 
discussing the impact of immunoproteasomes on NFB activation provides evidence for its 
involvement. T2 cells deficient in β1i/LMP2 and β5i/LMP7 have substantial defects in NFB activation 
upon TNF stimulation compared to the parental T1 cell line. They exhibited reduced nuclear levels 
of p50 and p52 as well as showed a defective IB degradation (Hayashi & Faustman 2000). Schmidt 
et al., reported that β5i/LMP7-/- mice developed attenuated DSS induced colitis in consequence of 
reduced NFB signaling due to a diminished nuclear translocation of p65. This resulted in a limited 
secretion of pro-inflammatory mediators, such as IL-1, IL-6, TNF, IFN, and IL-17, determined in 
colon of inflamed animals (Schmidt et al. 2010). Upon IFN stimulation, β5i/LMP7-/- cardiomyocytes 
and splenocytes had reduced levels of p50, reflecting reduced degradation of the NFB p105 
precursor protein by the proteasome (Opitz et al. 2011). Furthermore, IAV infected 1i/LMP2-/- DCs 
secreted significantly reduced levels of IFN, IL-6, IL-1, and TNF. This was associated with a 
delayed and less complete IB degradation and impaired NFB signaling documented in LPS 
stimulated B cells (Hensley et al. 2010). It is also possible that immunoproteasomes influence the 
signaling cascade upstream of NFB activation, like reported by Reis et al. who documented that LPS 
stimulated β5i/LMP7-/-/β2i/MECL-1-/- macrophages generated reduced NO but unaffected TNFα 
levels in consequence of an impaired TRIF/TRAM signaling (Reis et al. 2011). Although human PBMC 
pretreated with a β5i/LMP7 specific inhibitor and stimulated either with LPS or anti-CD3/CD28 
secreted reduced levels of TNF, IL-6, IL-23, IFN and IL-2 this experimental setup did not affect 
NFB activity in a reporter cell line (Muchamuel et al. 2009). This suggests that β5i/LMP7 also 
regulates cytokine production via an NFB–independent pathways 
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Another possible example for immuoproteasome involvement in signaling transduction is the 
transcription factor AP-1. In case of iNOS expression it has been reported that enhanced AP-1 DNA 
binding activity and cJun / cFos mRNA expression inhibited iNOS expression via binding at a silencer 
domain located in the iNOS promoter region (Pautz et al. 2010). AP-1 is also involved in PTX-3 
transcription. Its expression was induced upon cJun binding at an AP-1 binding site in the promoter 
region of PTX-3, demonstrated in cJun deficient cells upon EGF stimulation (Chang et al. 2015). 
Additionally, a JNK-specific inhibitor, but not inhibitors against ERKs or p38, blocked PTX-3 expression 
(Han et al. 2005). Gerber et al. reported that proteasome inhibition induced MAPK activation and 
cJun-dependent AP-1 activity with subsequent IL-8 induction in monocytes independent of NFB 
activation and without additional stimulus (Gerber et al. 2004). Similar results, concerning AP-1 
activation could be detected by analyzing β5i/LMP7-/- macrophages. These cells expressed higher 
levels of cJun, cFos, and ATF-2, which exhibited an enhanced phosphorylated status, even in the 
absence of stimulation. Furthermore, LPS stimulation or S. pneumoniae co-cultivation resulted in an 
AP-1 activation which was more pronounced in β5i/LMP7-/- cells (see figure 3.22A/B). This effect was 
confirmed by pretreating macrophages with a proteasome specific inhibitor (see figure 3.22C). 
Inhibition or alteration of the immunoproteasome may attenuate degradation of cJun and thus 
prolong its phosphorylated status. It is also possible that AP-1 activation is the consequence of 
diminished degradation of an up-stream kinase, such as IRAK-1 or MAPKs (JNK, ERK1/2, p38). 
Because immunoproteasomes have an enhanced ability to degrade oxidized, misfolded, and 
polyubiquitinated proteins, especially relevant under stress condition such as inflammation (Seifert 
et al. 2010), it is also possible that AP-1 activation is facilitated by enhanced proteotoxic and 
oxidative stress due to β5i/LMP7 deficiency. This is in accordance with previous publications. 
Cuschieri et al. reported a regulatory role of the proteasome in pathogen induced intracellular 
signaling upstream of AP-1. Proteasome inhibition attenuated IRAK-1 degradation resulting in the 
maintenance of IRAK-1 phosphorylation and activation. This enhanced IRAK-1 activation was 
associated with elevated activation of MAPKs (ERK, p38, JNK) which resulted in the activation of AP-
1. Thus, LPS stimulated macrophages pretreated with a proteasome inhibitor secreted increased 
levels of IL-10, unaffected amounts of IL-6, and decreased levels of IL-8 and TNF. (Cuschieri et al. 
2004). Kitamura et al. reported increased phosphorylation of p38 with subsequent IL-6 production 
upon stimulation, triggered by an accumulation of damaged proteins in cells expressing a non-
functional β5i/LMP7 mutant (Kitamura et al. 2011).  
Moreover, the activity of transcription factors is influenced by nuclear receptors such as PPAR/ 
They interact with pro-inflammatory transcription factors (like AP-1, NFB, STAT-1) and thereby 
modulate their transcriptional activity via a direct protein-protein interaction (Pautz et al. 2010). 
PPAR activation represses the induction of iNOS and supports the expression of PTX-3 in 
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macrophages (Pautz et al. 2010; Majai et al. 2007) and PPAR activation lowers CRP and MBL 
expression in liver (Blanquart et al. 2003; Rakhshandehroo et al. 2009). Like other transcription 
factors and nuclear receptors, PPARs are ubiquitinated and rapidly degraded by the proteasome 
(Genini & Catapano 2006). The involvement of especially immunoproteasomes in regulating PPAR/ 
activity has not been elucidated, yet. 
TLR triggering, cytokine stimulation, and proteotoxic as well as oxidative stress activates various 
intracellular signaling pathways that interact and influence each other, finally activating numerous 
transcription factors. For example, iNOS gene expression is differentially regulated by AP-1, NFB, 
Stat1, C/EBP, CREB, GATA, and NF-IL6 (Pautz et al. 2010; Malley et al. 2003). PTX-3 exhibit binding 
sequences in its promoter region for AP-1, NFB, SP1, PU-1, and NF-IL6 (He et al. 2007), and CRP 
displays binding sites for NFB, C/EBP, STAT3, and HNF1 (Cha-Molstad et al. 2000). Pathogen 
activated signaling pathways are complex and numerous nuclear factors, such as NFB and AP-1 but 
also several more, have been demonstrated to play critical roles in the subsequent expression of 
inflammatory mediators. However, in regard to the complexity of the intracellular signaling, 
redundancy among signaling cascades, influencing and compensating each other, is likely. This makes 
it difficult to clarify a selective impact of β5i/LMP7 deficiency on gene regulation. 
Conceivably, due to their diverse proteolytic properties different proteasome sub-types presumably 
influence gene transcription by differentially degrading specific regulatory proteins of endogenous 
signaling cascades that either inhibit or activate gene transcription. It may be possible that the 
diversity of proteasome sub-types are important to precisely adjust endogenous cell signaling and 
activity of transcription factors adapted for cell specific functions. 
 
4.5. Conclusion: β5i/LMP7 deficiency aggravates pneumococcal pneumonia in mice by 
diminishing expression of opsonizing molecules 
The absence of the catalytic immuno-subunit β5i/LMP7 in murine macrophages and liver changed 
their composition of proteasomes. The altered proteasome constitution, which was not influenced 
upon pneumococcal infection, modified pathogen induced intracellular signaling pathways resulting 
in reduced gene transcription of immune modulating molecules, including pentraxins, Ficolin A, and 
collectins. They either directly opsonize bacteria or promote complement mediated opsonization, 
facilitating opsophagocytosis of bacteria and their subsequent elimination. The diminished opsonin 
expression impaired the humoral innate immune response against invading pneumococci resulting in 
an aggravated systemic dissemination of S. pneumoniae in β5i/LMP7-/- mice. The impaired bacterial 
elimination is accompanied by a more severe case of pneumonia with early mortality in consequence 
of critical illness during the late phase of disease. 
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Abbreviations 
  
(v/v) Ratio volume to volume 
(w/v) Ratio weight to volumne 
19S  26 Svedberg 
26S 19 Svedberg 
a1-7 Proteasomal a subunit 1 to 7 
AIM2 Part of inflammasome, absent in melanoma 2 
ALAT Alanine transaminase 
AMC 7-amino-4-methylcoumarin 
AP-1 Activator protein 1 
APC Antigen presenting cell 
APS Ammonium peroxodisulfat 
ATF2 Activating transcription factor 2 
ATP Adenosine triphosphate 
b1-7 Proteasome b subunit 1 to 7 
BAL Bronchial alveolar lavage 
BCA Bicinchoninic acid protein assay 
bi-subunit Immuno-subunit 
BMM Bone marrow derived macrophages 
bp Base pair 
BSA Bovine serum albumine 
C3b Opsonizing complement factor 
CANDLE 
Chronic atrophical neutrophilic dermatosis with lipodystrophy and elevated temperature 
syndrome 
CASP Caspase 
CbpA Choline binding protein A 
cDNA Complementary DANN 
cfu Colony forming unit 
CPS Polysaccharide capsule 
CRP C reactive protein 
CTL Cytotoxic T lymphocyte 
CVB3 Coxsackievirus B3 
CXCL-1 Chemokine (C-X-C-motif) ligand 1 
D39 Streptococcus pneumoniae serotype 2 
Da Dalton, unit equal to g/mol 
DC Dendritic cell 
DEAE Diethylethanolamine 
DMSO Dimethyl sulfoxide 
DNA Desoxyribo nucleic acid 
DRFZ German Rheumatism Research Center Berlin 
DTT Dithiothreitol 
DUB Deubiquitinating enzyme 
E1 Ubiquitin activating enzyme 
E2 Ubiquitin conjugating enzyme 
E3 Ubiquitin ligating enzyme/ ligase 
EAE Experimental autoimmune encephalomyelitis 
EDTA Ethylene diamine tetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
Eno Enolase 
ERK Extracellular signal-regulated kinase 
FACS Fluorescence associated cell sorting 
FCS Fetal calf serum 
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FITC Fluorescein isothiocyanate 
G-CSF Granulocyte colony-stimulating factor 
h Hour 
HBV Hepatitis B Virus 
HIV Human immune-deficiency virus 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 
HRP Horse radish peroxidase 
Hyl Hyaluronidase 
IAV Influenza A virus 
IFN Interferon 
IgA1 IgA1 protease 
IgG Immunoglobulin G 
IkB I-kappa-B 
IKKε IkB kinase ε 
IL- Interleukin 
iNOS Inducible nitric oxide synthase 
IP-10 Interferon gamma-induced protein 10 
IRAK Interleukin-1 receptor-associated kinase 
IRF1 / 3 Interferon regulatory factor 1 / 3 
JASL Japanese autoinflammatory syndrome with lipodystrophy syndrome 
JMP 
Joint contractures, muscle atrophy, microcytic anaemia, and panniculitis-induced 
lipodystrophy syndrome 
JNK cjun N-terminal kinase 
K48 Lysine at amino acid position 48 
LCMV Lymphocytic Choriomeningitis Virus 
LDH Lactate dehydrogenase 
Lmp2 Low molecular mass protein 2, subunit beta1i 
Lmp7 Low molecular mass protein 7, subunit beta5i 
LPS Lipopolysaccharide 
LTA Lipoteichonic acid 
LytA Autolysin 
MACS Magnetic-activated cell sorting 
MAL MyD88 adapter-like protein 
MAPK Mitogen-activated protein kinase 
MASP Mannon-binding lectin serine protease 
MBL Mannose-binding lectin 
MCP-1 Monocyte chemotactic protein 1 
m-CSF Murine macrophage colony-stimulating factor 
Mecl-1 Multicatalytic endopeptidase complex subunit 1, subunit beta2i 
MEF Mouse embryonic fibroblast 
MHC Major histocompatibility complex 
mIFNg Murine interferon gamma 
min Minute 
MIP-1b Macrophage inflammatory protein-1b 
MKK Mitogen-activated protein kinase kinase 
MOI Multiplicity of infection 
MpH Macrophage 
mRNA Messenger RNA 
MyD88 Myeloid differentiation primary response gene 88 
NanA Neuraminidase 
mRNA Messenger RNA 
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NanA Neuraminidase  
NFkB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NLR Nod-like receptor 
NNS Nakajo-Nishimura syndrome 
NO Nitric oxide 
NO-2 Nitrite 
NOD2 Nucleotide-binding oligomerization domain-containing protein 2 
OD600 Optical density at wave length of 600nm 
P/S Penicillin/Streptomycin 
PA28 proteasome activator 28 
PAC1-4 Proteasome assembling chaperone 
PAGE polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecular pattern 
pavA Pneumococcal adhesion and virulence 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
PBST Phosphate buffered saline (with tween-20) 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PerCP Peridinin chlorophyll 
Ply Pneumolysin 
PN36 Streptococcus pneumoniae serotype 3 
POMP Proteasome maturation protein 
PPARa/g Peroxiyome proligerator-activated receptor 
PRR Pattern recognition receptor 
Psa Pneumococcal surface antigen A 
PSMB8 Proteasome subunit beta type 8 (coding for beta5i) 
PspA Pneumococcal surface protein A 
PTX-3 Pentraxin 3 
RIP1 Receptor interacting protein 1 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
Rpt Regulatory particle 
RT Reverse transcriptase  
RT-PCR Reverse transcriptase polymerase chain reaction 
SAA Serum amyloid A 
SAP Serum amyloid P 
SD Standard deviation 
SDS Sodiumdodecylsulfoxide 
sec Second 
SIRS Systmic inflammatory response syndrome 
SLE Systemic lupus erythematosus 
SP-A Surfactant protein A 
SP-D Surfactant protein D 
STAT 1 / 3 Signal transducer and activator of transcription 
STING Stimulator of interferon genes 
TBK1 TANK-binding kinease 1 
T-cytotox Cytotoxic T cell 
TEAD Tris, EDTA, acid, DTT 
TEMED Tetramethylethylenediamine 
TGFb Tissue growth factor 
Th T helper cell 
TLR Toll like receptor 
TNF Tumor necrosis factor 
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TRAF 3/6 TNF receptor associated factor 
Tram Translocating chain-associated membrane 
T-reg Regulators T cell 
Trif Tir-domain-containing adapter-inducing interferon b 
Tris Tris(hydroxymethyl)-aminomethan 
U Unit 
Ub Ubiquitin 
UPS Ubiquitin-proteasome system 
US United state 
UV Ultra violet 
WHO World Health Organisation 
WT Wild-type 
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